| Year |
Citation |
Score |
| 2024 |
Collij LE, Bischof GN, Altomare D, Bader I, Battle M, Vállez García D, Lopes Alves I, Wolz R, Gismondi R, Stephens A, Walker Z, Scheltens P, Nordberg A, Gispert JD, Drzezga A, et al. Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 39542700 DOI: 10.2967/jnumed.124.268119 |
0.374 |
|
| 2024 |
Lorenzini L, Maranzano A, Ingala S, Collij LE, Tranfa M, Blennow K, Di Perri C, Foley C, Fox NC, Frisoni GB, Haller S, Martinez-Lage P, Mollison D, O'Brien J, Payoux P, ... ... Scheltens P, et al. Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia. Neurology. 103: e209801. PMID 39288341 DOI: 10.1212/WNL.0000000000209801 |
0.484 |
|
| 2024 |
Lorenzini L, Collij LE, Tesi N, Vilor-Tejedor N, Ingala S, Blennow K, Foley C, Frisoni GB, Haller S, Holstege H, van der van der Lee S, Martinez-Lage P, Marioni RE, McCartney DL, O' Brien J, ... ... Scheltens P, et al. Alzheimer's disease genetic pathways impact cerebrospinal fluid biomarkers and imaging endophenotypes in non-demented individuals. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 39073684 DOI: 10.1002/alz.14096 |
0.432 |
|
| 2024 |
Ulugut H, Bertoux M, Younes K, Montembeault M, Fumagalli GG, Samanci B, Illán-Gala I, Kuchcinski G, Leroy M, Thompson JC, Kobylecki C, Santillo AF, Englund E, Waldö ML, Riedl L, ... ... Scheltens P, et al. Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 38982845 DOI: 10.1002/alz.14076 |
0.369 |
|
| 2024 |
Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, Molinuevo JL, Okonkwo OC, Pani L, Rafii MS, Scheltens P, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 38934362 DOI: 10.1002/alz.13859 |
0.301 |
|
| 2024 |
Bollack A, Collij LE, García DV, Shekari M, Altomare D, Payoux P, Dubois B, Grau-Rivera O, Boada M, Marquié M, Nordberg A, Walker Z, Scheltens P, Schöll M, Wolz R, et al. Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 38574374 DOI: 10.1002/alz.13761 |
0.366 |
|
| 2024 |
Hönig M, Altomare D, Caprioglio C, Collij L, Barkhof F, Van Berckel B, Scheltens P, Farrar G, Battle MR, Theis H, Giehl K, Bischof GN, Garibotto V, Molinuevo JLL, Grau-Rivera O, et al. Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease. Neurology. 102: e208053. PMID 38377442 DOI: 10.1212/WNL.0000000000208053 |
0.484 |
|
| 2023 |
Bader I, Bader I, Lopes Alves I, Vállez García D, Vellas B, Dubois B, Boada M, Marquié M, Altomare D, Scheltens P, Vandenberghe R, Hanseeuw B, Schöll M, Frisoni GB, Jessen F, et al. Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study. Alzheimer's Research & Therapy. 15: 189. PMID 37919783 DOI: 10.1186/s13195-023-01332-4 |
0.461 |
|
| 2023 |
Neumann A, Ohlei O, Küçükali F, Bos IJ, Timsina J, Vos S, Prokopenko D, Tijms BM, Andreasson U, Blennow K, Vandenberghe R, Scheltens P, Teunissen CE, Engelborghs S, Frisoni GB, et al. Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning. Genome Medicine. 15: 79. PMID 37794492 DOI: 10.1186/s13073-023-01233-z |
0.429 |
|
| 2023 |
Coomans EM, de Koning LA, Rikken RM, Verfaillie SCJ, Visser D, den Braber A, Tomassen J, van de Beek M, Collij LE, Lemstra AW, Windhorst AD, Barkhof F, Golla SSV, Visser PJ, Scheltens P, et al. Performance of a [F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies. Neurology. 101: e1850-e1862. PMID 37748892 DOI: 10.1212/WNL.0000000000207794 |
0.435 |
|
| 2023 |
van Amerongen S, Kamps S, Kaijser KKM, Pijnenburg YAL, Scheltens P, Teunissen CE, Barkhof F, Ossenkoppele R, Rozemuller AJM, Stern RA, Hoozemans JJM, Vijverberg EGB. Severe CTE and TDP-43 pathology in a former professional soccer player with dementia: a clinicopathological case report and review of the literature. Acta Neuropathologica Communications. 11: 77. PMID 37161501 DOI: 10.1186/s40478-023-01572-3 |
0.464 |
|
| 2023 |
Altomare D, Barkhof F, Caprioglio C, Collij LE, Scheltens P, Lopes Alves I, Bouwman F, Berkhof J, van Maurik IS, Garibotto V, Moro C, Delrieu J, Payoux P, Saint-Aubert L, Hitzel A, et al. Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial. Jama Neurology. PMID 37155177 DOI: 10.1001/jamaneurol.2023.0997 |
0.371 |
|
| 2023 |
Lorenzini L, Ingala S, Collij LE, Wottschel V, Haller S, Blennow K, Frisoni G, Chételat G, Payoux P, Lage-Martinez P, Ewers M, Waldman A, Wardlaw J, Ritchie C, Gispert JD, ... ... Scheltens P, et al. Eigenvector centrality dynamics are related to Alzheimer's disease pathological changes in non-demented individuals. Brain Communications. 5: fcad088. PMID 37151225 DOI: 10.1093/braincomms/fcad088 |
0.438 |
|
| 2023 |
van Nifterick AM, Mulder D, Duineveld DJ, Diachenko M, Scheltens P, Stam CJ, van Kesteren RE, Linkenkaer-Hansen K, Hillebrand A, Gouw AA. Resting-state oscillations reveal disturbed excitation-inhibition ratio in Alzheimer's disease patients. Scientific Reports. 13: 7419. PMID 37150756 DOI: 10.1038/s41598-023-33973-8 |
0.309 |
|
| 2023 |
Frisoni GB, Altomare D, Ribaldi F, Villain N, Brayne C, Mukadam N, Abramowicz M, Barkhof F, Berthier M, Bieler-Aeschlimann M, Blennow K, Brioschi Guevara A, Carrera E, Chételat G, Csajka C, ... ... Scheltens P, et al. Dementia prevention in memory clinics: recommendations from the European task force for brain health services. The Lancet Regional Health. Europe. 26: 100576. PMID 36895446 DOI: 10.1016/j.lanepe.2022.100576 |
0.404 |
|
| 2023 |
Coomans EM, Tomassen J, Ossenkoppele R, Tijms BM, Lorenzini L, Ten Kate M, Collij LE, Heeman F, Rikken RM, van der Landen SM, den Hollander ME, Golla SSV, Yaqub M, Windhorst AD, Barkhof F, ... Scheltens P, et al. Genetically identical twin-pair difference models support the amyloid cascade hypothesis. Brain : a Journal of Neurology. PMID 36892415 DOI: 10.1093/brain/awad077 |
0.388 |
|
| 2023 |
den Braber A, Verberk IMW, Tomassen J, den Dulk B, Stoops E, Dage JL, Collij LE, Barkhof F, Willemsen G, Nivard MG, van Berckel BNM, Scheltens P, Visser PJ, de Geus EJC, Teunissen CE. Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 years. Brain Communications. 5: fcad024. PMID 36824390 DOI: 10.1093/braincomms/fcad024 |
0.407 |
|
| 2023 |
van 't Hooft JJ, Pelkmans W, Tomassen J, Smits C, Legdeur N, den Braber A, Barkhof F, van Berckel B, Yaqub M, Scheltens P, Pijnenburg YA, Visser PJ, Tijms BM. Distinct disease mechanisms may underlie cognitive decline related to hearing loss in different age groups. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 36639225 DOI: 10.1136/jnnp-2022-329726 |
0.37 |
|
| 2023 |
Caprioglio C, Ribaldi F, Visser LNC, Minguillon C, Collij LE, Grau-Rivera O, Zeyen P, Molinuevo JL, Gispert JD, Garibotto V, Moro C, Walker Z, Edison P, Demonet JF, Barkhof F, ... Scheltens P, et al. Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline. Jama Network Open. 6: e2250921. PMID 36637820 DOI: 10.1001/jamanetworkopen.2022.50921 |
0.437 |
|
| 2022 |
Collij LE, Salvadó G, de Wilde A, Altomare D, Shekari M, Gispert JD, Bullich S, Stephens A, Barkhof F, Scheltens P, Bouwman F, van der Flier WM. Quantification of [ F]florbetaben amyloid-PET imaging in a mixed memory clinic population: The ABIDE project. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 36478646 DOI: 10.1002/alz.12886 |
0.32 |
|
| 2022 |
Küçükali F, Neumann A, Van Dongen J, De Pooter T, Joris G, De Rijk P, Ohlei O, Dobricic V, Bos I, Vos SJB, Engelborghs S, De Roeck E, Vandenberghe R, Gabel S, Meersmans K, ... ... Scheltens P, et al. Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 36464806 DOI: 10.1002/alz.12842 |
0.445 |
|
| 2022 |
Leijenaar JF, Ingala S, Sudre CH, Mutsaerts HM, Leeuwis AE, van der Flier WM, Scheltens P, Weinstein HC, Barkhof F, van Gerven J, Groeneveld GJ, Prins ND. Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. Cerebral Circulation - Cognition and Behavior. 3: 100128. PMID 36324417 DOI: 10.1016/j.cccb.2022.100128 |
0.453 |
|
| 2022 |
Boomsma JM, Exalto LG, Barkhof F, Leeuwis AE, Prins ND, Scheltens P, Teunissen CE, Weinstein HC, Biessels GJ, van der Flier WM. Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study. Cerebral Circulation - Cognition and Behavior. 3: 100141. PMID 36324410 DOI: 10.1016/j.cccb.2022.100141 |
0.39 |
|
| 2022 |
Ebenau JL, Visser D, Verfaillie SCJ, Timmers T, van Leeuwenstijn MSSA, Kate MT, Windhorst AD, Barkhof F, Scheltens P, Prins ND, Boellaard R, van der Flier WM, van Berckel BNM. Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals. European Journal of Nuclear Medicine and Molecular Imaging. PMID 36071221 DOI: 10.1007/s00259-022-05958-8 |
0.424 |
|
| 2022 |
Ebenau JL, Visser D, Kroeze LA, van Leeuwenstijn MSSA, van Harten AC, Windhorst AD, Golla SVS, Boellaard R, Scheltens P, Barkhof F, van Berckel BNM, van der Flier WM. Longitudinal change in ATN biomarkers in cognitively normal individuals. Alzheimer's Research & Therapy. 14: 124. PMID 36057616 DOI: 10.1186/s13195-022-01069-6 |
0.415 |
|
| 2022 |
van Amerongen S, Caton DK, Ossenkoppele R, Barkhof F, Pouwels PJW, Teunissen CE, Rozemuller AJM, Hoozemans JJM, Pijnenburg YAL, Scheltens P, Vijverberg EGB. Rationale and design of the "NEurodegeneration: Traumatic brain injury as Origin of the Neuropathology (NEwTON)" study: a prospective cohort study of individuals at risk for chronic traumatic encephalopathy. Alzheimer's Research & Therapy. 14: 119. PMID 36050790 DOI: 10.1186/s13195-022-01059-8 |
0.357 |
|
| 2022 |
Ulugut H, Trieu C, Groot C, van 't Hooft JJ, Tijms BM, Scheltens P, Ossenkoppele R, Barkhof F, van den Heuvel OA, Pijnenburg YAL. Overlap of Neuroanatomical Involvement in Frontotemporal Dementia and Primary Psychiatric Disorders: A Meta-analysis. Biological Psychiatry. PMID 35965106 DOI: 10.1016/j.biopsych.2022.05.028 |
0.324 |
|
| 2022 |
Mank A, van Maurik IS, Rijnhart JJM, Bakker ED, Bouteloup V, Le Scouarnec L, Teunissen CE, Barkhof F, Scheltens P, Berkhof J, van der Flier WM. Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer's disease. Alzheimer's Research & Therapy. 14: 110. PMID 35932034 DOI: 10.1186/s13195-022-01053-0 |
0.437 |
|
| 2022 |
Altomare D, Collij L, Caprioglio C, Scheltens P, van Berckel BNM, Alves IL, Berkhof J, de Gier Y, Garibotto V, Moro C, Poitrine L, Delrieu J, Payoux P, Saint-Aubert L, Molinuevo JL, et al. Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 35715930 DOI: 10.1002/alz.12696 |
0.344 |
|
| 2022 |
Delvenne A, Gobom J, Tijms B, Bos I, Reus LM, Dobricic V, Kate MT, Verhey F, Ramakers I, Scheltens P, Teunissen CE, Vandenberghe R, Schaeverbeke J, Gabel S, Popp J, et al. Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 35698882 DOI: 10.1002/alz.12713 |
0.471 |
|
| 2022 |
Dubbelman MA, Verrijp M, Terwee CB, Jutten RJ, Postema MC, Barkhof F, Berckel BNM, Gillissen F, Teeuwen V, Teunissen C, van de Flier WM, Scheltens P, Sikkes SAM. Pursuing Clinical Meaningfulness: Determining the Minimal Important Change of Everyday Functioning in Dementia. Neurology. PMID 35641309 DOI: 10.1212/WNL.0000000000200781 |
0.365 |
|
| 2022 |
Exalto LG, Hendriksen HMA, Barkhof F, van den Bosch KA, Ebenau JL, van Leeuwenstijn-Koopman M, Prins ND, Teunissen CE, Visser LNC, Scheltens P, van der Flier WM. Subjective cognitive decline and self-reported sleep problems: The SCIENCe project. Alzheimer's & Dementia (Amsterdam, Netherlands). 14: e12287. PMID 35603141 DOI: 10.1002/dad2.12287 |
0.308 |
|
| 2022 |
Homann J, Osburg T, Ohlei O, Dobricic V, Deecke L, Bos I, Vandenberghe R, Gabel S, Scheltens P, Teunissen CE, Engelborghs S, Frisoni G, Blin O, Richardson JC, Bordet R, et al. Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience. 14: 840651. PMID 35386118 DOI: 10.3389/fnagi.2022.840651 |
0.462 |
|
| 2022 |
van Loenhoud AC, Groot C, Bocancea DI, Barkhof F, Teunissen C, Scheltens P, van de Flier WM, Ossenkoppele R. Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum. Neurology. 98: e1679-e1691. PMID 35314498 DOI: 10.1212/WNL.0000000000200116 |
0.453 |
|
| 2022 |
Pelkmans W, Vromen EM, Dicks E, Scheltens P, Teunissen CE, Barkhof F, van der Flier WM, Tijms BM. Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline. Brain Communications. 4: fcac026. PMID 35310828 DOI: 10.1093/braincomms/fcac026 |
0.511 |
|
| 2022 |
Collij LE, Salvadó G, Wottschel V, Mastenbroek SE, Schoenmakers P, Heeman F, Aksman L, Wink AM, Berckel BNM, van de Flier WM, Scheltens P, Visser PJ, Barkhof F, Haller S, Gispert JD, et al. Spatial-Temporal Patterns of Amyloid-β Accumulation: A Subtype and Stage Inference Model Analysis. Neurology. PMID 35292558 DOI: 10.1212/WNL.0000000000200148 |
0.328 |
|
| 2022 |
Vromen EM, Del Campo Milán M, Scheltens P, Teunissen CE, Visser PJ, Tijms BM. CSF proteomic signature predicts progression to Alzheimer's disease dementia. Alzheimer's & Dementia (New York, N. Y.). 8: e12240. PMID 35229020 DOI: 10.1002/trc2.12240 |
0.342 |
|
| 2022 |
Verhaar BJH, Hendriksen HMA, de Leeuw FA, Doorduijn AS, van Leeuwenstijn M, Teunissen CE, Barkhof F, Scheltens P, Kraaij R, van Duijn CM, Nieuwdorp M, Muller M, van der Flier WM. Gut Microbiota Composition Is Related to AD Pathology. Frontiers in Immunology. 12: 794519. PMID 35173707 DOI: 10.3389/fimmu.2021.794519 |
0.484 |
|
| 2022 |
Neumann A, Küçükali F, Bos I, Vos SJB, Engelborghs S, De Pooter T, Joris G, De Rijk P, De Roeck E, Tsolaki M, Verhey F, Martinez-Lage P, Tainta M, Frisoni G, Blin O, ... ... Scheltens P, et al. Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry. PMID 35173266 DOI: 10.1038/s41380-022-01437-6 |
0.382 |
|
| 2022 |
van der Schaar J, Visser LNC, Bouwman FH, Ket JCF, Scheltens P, Bredenoord AL, van der Flier WM. Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review. Alzheimer's Research & Therapy. 14: 31. PMID 35144684 DOI: 10.1186/s13195-022-00971-3 |
0.311 |
|
| 2022 |
Ebenau JL, Pelkmans W, Verberk IMW, Verfaillie S, van den Bosch KA, van Leeuwenstijn M, Collij L, Scheltens P, Prins N, Barkhof F, van Berckel B, Teunissen CE, Van der Flier WM. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. Neurology. PMID 35110378 DOI: 10.1212/WNL.0000000000200035 |
0.401 |
|
| 2022 |
van de Beek M, Ooms FAH, Ebenau JL, Barkhof F, Scheltens P, Teunissen CE, van Harten AC, van der Flier WM, Lemstra AW. Association of the ATN Research Framework With Clinical Profile, Ccognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. Neurology. PMID 35074893 DOI: 10.1212/WNL.0000000000200048 |
0.461 |
|
| 2022 |
Coomans EM, Tomassen J, Ossenkoppele R, Golla SSV, den Hollander M, Collij LE, Weltings E, van der Landen S, Wolters EE, Windhorst AD, Barkhof F, de Geus EJC, Scheltens P, Visser PJ, van Berckel BNM, et al. Genetically identical twins show comparable tau PET load and spatial distribution. Brain : a Journal of Neurology. PMID 35022652 DOI: 10.1093/brain/awac004 |
0.344 |
|
| 2021 |
Salvadó G, Ferreira D, Operto G, Cumplido-Mayoral I, Arenaza-Urquijo EM, Cacciaglia R, Falcon C, Vilor-Tejedor N, Minguillon C, Groot C, van der Flier WM, Barkhof F, Scheltens P, Ossenkoppele R, Kern S, et al. The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 34877786 DOI: 10.1002/alz.12487 |
0.436 |
|
| 2021 |
Ranson JM, Rittman T, Hayat S, Brayne C, Jessen F, Blennow K, van Duijn C, Barkhof F, Tang E, Mummery CJ, Stephan BCM, Altomare D, Frisoni GB, Ribaldi F, Molinuevo JL, ... Scheltens P, et al. Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6. Alzheimer's Research & Therapy. 13: 169. PMID 34635138 DOI: 10.1186/s13195-021-00895-4 |
0.351 |
|
| 2021 |
Ingala S, Tomassen J, Collij LE, Prent N, van 't Ent D, Ten Kate M, Konijnenberg E, Yaqub M, Scheltens P, de Geus EJC, Teunissen CE, Tijms B, Wink AM, Barkhof F, van Berckel BNM, et al. Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. Brain Communications. 3: fcab201. PMID 34617016 DOI: 10.1093/braincomms/fcab201 |
0.371 |
|
| 2021 |
Ebenau JL, van der Lee SJ, Hulsman M, Tesi N, Jansen IE, Verberk IMW, van Leeuwenstijn M, Teunissen CE, Barkhof F, Prins ND, Scheltens P, Holstege H, van Berckel BNM, van der Flier WM. Risk of dementia in ε4 carriers is mitigated by a polygenic risk score. Alzheimer's & Dementia (Amsterdam, Netherlands). 13: e12229. PMID 34541285 DOI: 10.1002/dad2.12229 |
0.43 |
|
| 2021 |
Ulugut H, Dijkstra AA, Scarioni M, Barkhof F, Scheltens P, Rozemuller AJM, Pijnenburg YAL. Right temporal variant frontotemporal dementia is pathologically heterogeneous: a case-series and a systematic review. Acta Neuropathologica Communications. 9: 131. PMID 34344452 DOI: 10.1186/s40478-021-01229-z |
0.364 |
|
| 2021 |
Ulugut H, Stek S, Wagemans LEE, Jutten RJ, Keulen MA, Bouwman FH, Prins ND, Lemstra AW, Krudop W, Teunissen CE, van Berckel BNM, Ossenkoppele R, Barkhof F, van der Flier WM, Scheltens P, et al. The natural history of primary progressive aphasia: beyond aphasia. Journal of Neurology. PMID 34216263 DOI: 10.1007/s00415-021-10689-1 |
0.32 |
|
| 2021 |
Groot C, Risacher SL, Chen JQA, Dicks E, Saykin AJ, Mac Donald CL, Mez J, Trittschuh EH, Mukherjee S, Barkhof F, Scheltens P, van der Flier WM, Ossenkoppele R, Crane PK. Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups. Neuroimage. Clinical. 31: 102725. PMID 34153688 DOI: 10.1016/j.nicl.2021.102725 |
0.472 |
|
| 2021 |
Hong S, Dobricic V, Ohlei O, Bos I, Vos SJB, Prokopenko D, Tijms BM, Andreasson U, Blennow K, Vandenberghe R, Gabel S, Scheltens P, Teunissen CE, Engelborghs S, Frisoni G, et al. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 33991015 DOI: 10.1002/alz.12330 |
0.419 |
|
| 2021 |
Groot C, Grothe MJ, Mukherjee S, Jelistratova I, Jansen I, van Loenhoud AC, Risacher SL, Saykin AJ, Mac Donald CL, Mez J, Trittschuh EH, Gryglewski G, Lanzenberger R, Pijnenburg YAL, Barkhof F, ... Scheltens P, et al. Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. Neuroimage. Clinical. 30: 102660. PMID 33895633 DOI: 10.1016/j.nicl.2021.102660 |
0.462 |
|
| 2021 |
van Engelen ME, Rozemuller AJM, Ulugut Erkoyun H, Groot C, Fieldhouse JLP, Koene T, Ossenkoppele R, Gossink FT, Krudop WA, Vijverberg EGB, Dols A, Barkhof F, Berckel BNMV, Scheltens P, Brain Bank N, et al. The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [F]FDG-PET and pathological assessment. Neurocase. 1-9. PMID 33881963 DOI: 10.1080/13554794.2021.1905855 |
0.346 |
|
| 2021 |
Briels CT, Stam CJ, Scheltens P, Gouw AA. The predictive value of normal EEGs in dementia due to Alzheimer's disease. Annals of Clinical and Translational Neurology. PMID 33835723 DOI: 10.1002/acn3.51339 |
0.324 |
|
| 2021 |
Collij LE, Ingala S, Top H, Wottschel V, Stickney KE, Tomassen J, Konijnenberg E, Ten Kate M, Sudre C, Lopes Alves I, Yaqub MM, Wink AM, Van 't Ent D, Scheltens P, van Berckel BNM, et al. White matter microstructure disruption in early stage amyloid pathology. Alzheimer's & Dementia (Amsterdam, Netherlands). 13: e12124. PMID 33816751 DOI: 10.1002/dad2.12124 |
0.473 |
|
| 2021 |
Ingala S, De Boer C, Masselink LA, Vergari I, Lorenzini L, Blennow K, Chételat G, Di Perri C, Ewers M, van der Flier WM, Fox NC, Gispert JD, Haller S, Molinuevo JL, Muniz-Terrera G, ... ... Scheltens P, et al. Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 33811742 DOI: 10.1002/alz.12292 |
0.412 |
|
| 2021 |
Shi L, Winchester LM, Westwood S, Baird AL, Anand SN, Buckley NJ, Hye A, Ashton NJ, Bos I, Vos SJB, Kate MT, Scheltens P, Teunissen CE, Vandenberghe R, Gabel S, et al. Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 33792144 DOI: 10.1002/alz.12322 |
0.436 |
|
| 2021 |
Collij LE, Salvadó G, Shekari M, Alves IL, Reimand J, Wink AM, Zwan M, Niñerola-Baizán A, Perissinotti A, Scheltens P, Ikonomovic MD, Smith APL, Farrar G, Molinuevo JL, Barkhof F, et al. Visual assessment of [F]flutemetamol PET images can detect early amyloid pathology and grade its extent. European Journal of Nuclear Medicine and Molecular Imaging. PMID 33615397 DOI: 10.1007/s00259-020-05174-2 |
0.32 |
|
| 2021 |
Konijnenberg E, Tomassen J, den Braber A, Ten Kate M, Yaqub MM, Mulder SD, Nivard MG, Vanderstichele H, Lammertsma AA, Teunissen CE, van Berckel BNM, Boomsma DI, Scheltens P, Tijms BM, Visser PJ. The onset of preclinical Alzheimer's disease in monozygotic twins. Annals of Neurology. PMID 33583080 DOI: 10.1002/ana.26048 |
0.3 |
|
| 2021 |
Cicognola C, Hansson O, Scheltens P, Kvartsberg H, Zetterberg H, Teunissen CE, Blennow K. Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. Alzheimer's Research & Therapy. 13: 38. PMID 33557920 DOI: 10.1186/s13195-020-00756-6 |
0.329 |
|
| 2021 |
Coomans EM, Schoonhoven DN, Tuncel H, Verfaillie SCJ, Wolters EE, Boellaard R, Ossenkoppele R, den Braber A, Scheper W, Schober P, Sweeney SP, Ryan JM, Schuit RC, Windhorst AD, Barkhof F, ... Scheltens P, et al. In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimer's Research & Therapy. 13: 35. PMID 33546722 DOI: 10.1186/s13195-021-00772-0 |
0.335 |
|
| 2021 |
Erkoyun HU, van der Lee SJ, Nijmeijer B, Spaendonk RV, Nelissen A, Scarioni M, Dijkstra A, Samancı B, Gürvit H, Yıldırım Z, Tepgeç F, Bilgic B, Barkhof F, Rozemuller A, van der Flier WM, ... Scheltens P, et al. The Right Temporal Variant of Frontotemporal Dementia is Not Genetically Sporadic: A Case Series. Journal of Alzheimer's Disease : Jad. PMID 33427744 DOI: 10.3233/JAD-201191 |
0.342 |
|
| 2021 |
Pelkmans W, Legdeur N, Ten Kate M, Barkhof F, Yaqub MM, Holstege H, van Berckel BNM, Scheltens P, van der Flier WM, Visser PJ, Tijms BM. Amyloid-β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. Annals of Clinical and Translational Neurology. PMID 33421355 DOI: 10.1002/acn3.51273 |
0.405 |
|
| 2021 |
van Maurik IS, Rhodius-Meester HFM, Teunissen CE, Scheltens P, Barkhof F, Palmqvist S, Hansson O, van der Flier WM, Berkhof J. Biomarker testing in MCI patients-deciding who to test. Alzheimer's Research & Therapy. 13: 14. PMID 33413634 DOI: 10.1186/s13195-020-00763-7 |
0.406 |
|
| 2020 |
Tijms BM, Gobom J, Reus L, Jansen I, Hong S, Dobricic V, Kilpert F, Ten Kate M, Barkhof F, Tsolaki M, Verhey FRJ, Popp J, Martinez-Lage P, Vandenberghe R, Lleó A, ... ... Scheltens P, et al. Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain : a Journal of Neurology. 143: 3776-3792. PMID 33439986 DOI: 10.1093/brain/awaa325 |
0.499 |
|
| 2020 |
de Leeuw FA, Tijms BM, Doorduijn AS, Hendriksen HMA, van de Rest O, de van der Schueren MAE, Visser M, van den Heuvel EGHM, van Wijk N, Bierau J, van Berckel BN, Scheltens P, Kester MI, van der Flier WM, Teunissen CE. LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12120. PMID 33392381 DOI: 10.1002/dad2.12120 |
0.331 |
|
| 2020 |
Dicks E, Vermunt L, van der Flier WM, Barkhof F, Scheltens P, Tijms BM. Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. Brain Communications. 2: fcaa177. PMID 33376987 DOI: 10.1093/braincomms/fcaa177 |
0.472 |
|
| 2020 |
Stockmann J, Verberk IMW, Timmesfeld N, Denz R, Budde B, Lange-Leifhelm J, Scheltens P, van der Flier WM, Nabers A, Teunissen CE, Gerwert K. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. Alzheimer's Research & Therapy. 12: 169. PMID 33357241 DOI: 10.1186/s13195-020-00738-8 |
0.336 |
|
| 2020 |
Doorduijn AS, de van der Schueren MAE, van de Rest O, de Leeuw FA, Hendriksen HMA, Teunissen CE, Scheltens P, van der Flier WM, Visser M. Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. Journal of the American Medical Directors Association. PMID 33239240 DOI: 10.1016/j.jamda.2020.10.020 |
0.314 |
|
| 2020 |
Hong S, Prokopenko D, Dobricic V, Kilpert F, Bos I, Vos SJB, Tijms BM, Andreasson U, Blennow K, Vandenberghe R, Cleynen I, Gabel S, Schaeverbeke J, Scheltens P, Teunissen CE, et al. Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry. 10: 403. PMID 33223526 DOI: 10.1038/s41398-020-01074-z |
0.449 |
|
| 2020 |
Singleton EH, Pijnenburg YAL, Sudre CH, Groot C, Kochova E, Barkhof F, La Joie R, Rosen HJ, Seeley WW, Miller B, Cardoso MJ, Papma J, Scheltens P, Rabinovici GD, Ossenkoppele R. Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. Alzheimer's Research & Therapy. 12: 148. PMID 33189136 DOI: 10.1186/s13195-020-00717-z |
0.403 |
|
| 2020 |
Dubbelman MA, Jutten RJ, Tomaszewski Farias SE, Amariglio RE, Buckley RF, Visser PJ, Rentz DM, Johnson KA, Properzi MJ, Schultz A, Donovan N, Gatchell JR, Teunissen CE, Van Berckel BNM, Van der Flier WM, ... ... Scheltens P, et al. Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimer's Research & Therapy. 12: 138. PMID 33121534 DOI: 10.1186/s13195-020-00706-2 |
0.327 |
|
| 2020 |
Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, van de Giessen E, Agosta F, Barkhof F, Brooks DJ, Carrillo MC, Dubois B, Fjell AM, Frisoni GB, Hansson O, ... ... Scheltens P, et al. Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. The Lancet. Neurology. 19: 951-962. PMID 33098804 DOI: 10.1016/S1474-4422(20)30314-8 |
0.364 |
|
| 2020 |
Jutten RJ, Sikkes SAM, Amariglio RE, Buckley RF, Properzi MJ, Marshall GA, Rentz DM, Johnson KA, Teunissen CE, Van Berckel BNM, Van der Flier WM, Scheltens P, Sperling RA, Papp KV, et al. Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. Journal of the International Neuropsychological Society : Jins. 1-13. PMID 33046162 DOI: 10.1017/S1355617720000934 |
0.377 |
|
| 2020 |
Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A, Zwan MD, Verfaillie SCJ, Ossenkoppele R, Barkhof F, van Berckel BNM, Scheltens P, van der Flier WM, Stoops E, Vanderstichele HM, et al. Combination of plasma amyloid beta and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer's Research & Therapy. 12: 118. PMID 32988409 DOI: 10.1186/s13195-020-00682-7 |
0.407 |
|
| 2020 |
Doorduijn AS, de van der Schueren MAE, van de Rest O, de Leeuw FA, Hendriksen HMA, Teunissen CE, Scheltens P, van der Flier WM, Visser M. Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: the NUDAD project. Alzheimer's Research & Therapy. 12: 116. PMID 32979927 DOI: 10.1186/s13195-020-00687-2 |
0.345 |
|
| 2020 |
Hanes J, Kovac A, Kvartsberg H, Kontsekova E, Fialova L, Katina S, Kovacech B, Stevens E, Hort J, Vyhnalek M, Boonkamp L, Novak M, Zetterberg H, Hansson O, Scheltens P, et al. Evaluation of a novel immunoassay to detect p-Tau Thr127 in the CSF to distinguish Alzheimer disease from other dementias. Neurology. PMID 32973122 DOI: 10.1212/WNL.0000000000010814 |
0.329 |
|
| 2020 |
de Vent NR, Agelink van Rentergem JA, Huizenga HM, van der Flier WM, Sikkes SAM, Murre JMJ, van den Bosch KA, Scheltens P, Schmand BA. An Operational Definition of 'Abnormal Cognition' to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons? Journal of Alzheimer's Disease : Jad. PMID 32925072 DOI: 10.3233/Jad-200811 |
0.369 |
|
| 2020 |
van Engelen ME, Gossink FT, de Vijlder LS, Meursing JRA, Scheltens P, Dols A, Pijnenburg YAL. End Stage Clinical Features and Cause of Death of Behavioral Variant Frontotemporal Dementia and Young-Onset Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 77: 1169-1180. PMID 32925036 DOI: 10.3233/Jad-200337 |
0.363 |
|
| 2020 |
Reimand J, Collij L, Scheltens P, Bouwman F, Ossenkoppele R. Association of amyloid-β CSF/PET discordance and tau load five years later. Neurology. PMID 32913020 DOI: 10.1212/Wnl.0000000000010739 |
0.321 |
|
| 2020 |
Briels CT, Eertink JJ, Stam CJ, van der Flier WM, Scheltens P, Gouw AA. Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study. Neurobiology of Aging. 96: 1-11. PMID 32905950 DOI: 10.1016/J.Neurobiolaging.2020.07.029 |
0.41 |
|
| 2020 |
Legdeur N, Badissi M, Yaqub M, Beker N, Sudre CH, Ten Kate M, Gordon MF, Novak G, Barkhof F, van Berckel BNM, Holstege H, Muller M, Scheltens P, Maier AB, Visser PJ. What determines cognitive functioning in the oldest-old? The EMIF-AD 90+ Study. The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences. PMID 32898275 DOI: 10.1093/Geronb/Gbaa152 |
0.502 |
|
| 2020 |
de Leeuw FA, Karamujić-Čomić H, Tijms BM, Peeters CFW, Kester MI, Scheltens P, Ahmad S, Vojinovic D, Adams HHH, Hankemeier T, Bos D, van der Lugt A, Vernooij MW, Ikram MA, Amin N, et al. Circulating metabolites are associated with brain atrophy and white matter hyperintensities. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32886448 DOI: 10.1002/Alz.12180 |
0.413 |
|
| 2020 |
Rhodius-Meester HFM, Paajanen T, Koikkalainen J, Mahdiani S, Bruun M, Baroni M, Lemstra AW, Scheltens P, Herukka SK, Pikkarainen M, Hall A, Hänninen T, Ngandu T, Kivipelto M, van Gils M, et al. cCOG: A web-based cognitive test tool for detecting neurodegenerative disorders. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12083. PMID 32864411 DOI: 10.1002/Dad2.12083 |
0.367 |
|
| 2020 |
Shi L, Winchester LM, Liu BY, Killick R, Ribe EM, Westwood S, Baird AL, Buckley NJ, Hong S, Dobricic V, Kilpert F, Franke A, Kiddle S, Sattlecker M, Dobson R, ... ... Scheltens P, et al. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease : Jad. PMID 32831200 DOI: 10.3233/Jad-200208 |
0.507 |
|
| 2020 |
Ulugut Erkoyun H, Groot C, Heilbron R, Nelissen A, van Rossum J, Jutten R, Koene T, van der Flier WM, Wattjes MP, Scheltens P, Ossenkoppele R, Barkhof F, Pijnenburg Y. A clinical-radiological framework of the right temporal variant of frontotemporal dementia. Brain : a Journal of Neurology. PMID 32830218 DOI: 10.1093/Brain/Awaa225 |
0.513 |
|
| 2020 |
Frisoni GB, Molinuevo JL, Altomare D, Carrera E, Barkhof F, Berkhof J, Delrieu J, Dubois B, Kivipelto M, Nordberg A, Schott JM, van der Flier WM, Vellas B, Jessen F, Scheltens P, et al. Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32815289 DOI: 10.1002/Alz.12132 |
0.496 |
|
| 2020 |
Verhaar BJH, de Leeuw FA, Doorduijn AS, Fieldhouse JLP, van de Rest O, Teunissen CE, van Berckel BNM, Barkhof F, Visser M, de van der Schueren MAE, Scheltens P, Kester MI, Muller M, van der Flier WM. Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12063. PMID 32793798 DOI: 10.1002/Dad2.12063 |
0.541 |
|
| 2020 |
Mok VCT, Pendlebury S, Wong A, Alladi S, Au L, Bath PM, Biessels GJ, Chen C, Cordonnier C, Dichgans M, Dominguez J, Gorelick PB, Kim S, Kwok T, Greenberg SM, ... ... Scheltens P, et al. Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32789951 DOI: 10.1002/Alz.12143 |
0.327 |
|
| 2020 |
Boomsma JMF, Exalto LG, Barkhof F, Chen CLH, Hilal S, Leeuwis AE, Prins ND, Saridin FN, Scheltens P, Teunissen CE, Verwer JH, Weinstein HC, van der Flier WM, Biessels GJ. Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12077. PMID 32789162 DOI: 10.1002/Dad2.12077 |
0.463 |
|
| 2020 |
Mofrad RB, Tijms BM, Scheltens P, Barkhof F, van der Flier WM, Am Sikkes S, Teunissen CE. Sex differences in CSF biomarkers vary by Alzheimer's disease stage and APOE ε4 genotype. Neurology. PMID 32788242 DOI: 10.1212/Wnl.0000000000010629 |
0.472 |
|
| 2020 |
Heinen R, Groeneveld ON, Barkhof F, de Bresser J, Exalto LG, Kuijf HJ, Prins ND, Scheltens P, van der Flier WM, Biessels GJ. Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12060. PMID 32695872 DOI: 10.1002/Dad2.12060 |
0.485 |
|
| 2020 |
Groot C, Yeo BTT, Vogel JW, Zhang X, Sun N, Mormino EC, Pijnenburg YAL, Miller BL, Rosen HJ, Joie R, Barkhof F, Scheltens P, van der Flier WM, Rabinovici GD, Ossenkoppele R. Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. Neurology. PMID 32675078 DOI: 10.1212/Wnl.0000000000010362 |
0.443 |
|
| 2020 |
de Leeuw FA, van de Rest O, Doorduijn AS, Fieldhouse JLP, de van der Schueren MAE, Visser M, van den Heuvel EGHM, Scheltens P, Teunissen CE, Kester MI, van der Flier WM. Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. Journal of the American Medical Directors Association. PMID 32641272 DOI: 10.1016/J.Jamda.2020.04.031 |
0.399 |
|
| 2020 |
Joanne van der Zande J, Gouw AA, van Steenoven I, van de Beek M, Scheltens P, Stam CJ, Lemstra AW. Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies. Neurology. PMID 32636325 DOI: 10.1212/Wnl.0000000000009977 |
0.474 |
|
| 2020 |
Kivipelto M, Mangialasche F, Snyder HM, Allegri R, Andrieu S, Arai H, Baker L, Belleville S, Brodaty H, Brucki SM, Calandri I, Caramelli P, Chen C, Chertkow H, Chew E, ... ... Scheltens P, et al. World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32627328 DOI: 10.1002/Alz.12123 |
0.358 |
|
| 2020 |
Muurling M, Rhodius-Meester HFM, Pärkkä J, van Gils M, Frederiksen KS, Bruun M, Hasselbalch SG, Soininen H, Herukka SK, Hallikainen M, Teunissen CE, Visser PJ, Scheltens P, van der Flier WM, Mattila J, et al. Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. Journal of Alzheimer's Disease : Jad. PMID 32597806 DOI: 10.3233/Jad-200225 |
0.477 |
|
| 2020 |
Dicks E, van der Flier WM, Scheltens P, Barkhof F, Tijms BM. Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. Neurobiology of Aging. 94: 71-80. PMID 32585492 DOI: 10.1016/J.Neurobiolaging.2020.05.008 |
0.561 |
|
| 2020 |
de Vos F, Schouten TM, Koini M, Bouts MJRJ, Feis RA, Lechner A, Schmidt R, van Buchem MA, Verhey FRJ, Olde Rikkert MGM, Scheltens P, de Rooij M, van der Grond J, Rombouts SARB. Pre-trained MRI-based Alzheimer's disease classification models to classify memory clinic patients. Neuroimage. Clinical. 27: 102303. PMID 32554321 DOI: 10.1016/J.Nicl.2020.102303 |
0.438 |
|
| 2020 |
Staekenborg SS, Kelly N, Schuur J, Koster P, Scherder E, Tielkes CEM, Scheltens P, Claus JJ. Education as Proxy for Cognitive Reserve in a Large Elderly Memory Clinic: 'Window of Benefit'. Journal of Alzheimer's Disease : Jad. PMID 32538838 DOI: 10.3233/Jad-191332 |
0.57 |
|
| 2020 |
Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, van Harten AC, Teunissen CE, Barkhof F, van den Bosch KA, van Leeuwenstijn M, Tomassen J, Braber AD, Visser PJ, Prins ND, ... ... Scheltens P, et al. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. Neurology. PMID 32522798 DOI: 10.1212/Wnl.0000000000009724 |
0.507 |
|
| 2020 |
Briels CT, Schoonhoven DN, Stam CJ, de Waal H, Scheltens P, Gouw AA. Reproducibility of EEG functional connectivity in Alzheimer's disease. Alzheimer's Research & Therapy. 12: 68. PMID 32493476 DOI: 10.1186/S13195-020-00632-3 |
0.435 |
|
| 2020 |
Galasko D, Scheltens P. A decade of Alzheimer's Research & Therapy: reflections on the past, present, and future. Alzheimer's Research & Therapy. 12: 67. PMID 32473646 DOI: 10.1186/S13195-020-00629-Y |
0.308 |
|
| 2020 |
Visser D, Wolters EE, Verfaillie SCJ, Coomans EM, Timmers T, Tuncel H, Reimand J, Boellaard R, Windhorst AD, Scheltens P, van der Flier WM, Ossenkoppele R, van Berckel BNM. Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging. PMID 32462397 DOI: 10.1007/S00259-020-04831-W |
0.442 |
|
| 2020 |
Konijnenberg E, Tijms BM, Gobom J, Dobricic V, Bos I, Vos S, Tsolaki M, Verhey F, Popp J, Martinez-Lage P, Vandenberghe R, Lleó A, Frölich L, Lovestone S, Streffer J, ... ... Scheltens P, et al. APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. Alzheimer's Research & Therapy. 12: 65. PMID 32460813 DOI: 10.1186/S13195-020-00628-Z |
0.418 |
|
| 2020 |
Biessels GJ, Nobili F, Teunissen CE, Simó R, Scheltens P. Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. The Lancet. Neurology. PMID 32445622 DOI: 10.1016/S1474-4422(20)30139-3 |
0.37 |
|
| 2020 |
Ahmad S, Milan MDC, Hansson O, Demirkan A, Agustin R, Sáez ME, Giagtzoglou N, Cabrera-Socorro A, Bakker MHM, Ramirez A, Hankemeier T, Stomrud E, Mattsson-Carlgren N, Scheltens P, van der Flier WM, et al. CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE ε4 carriers. Scientific Reports. 10: 8233. PMID 32427856 DOI: 10.1038/S41598-020-65038-5 |
0.387 |
|
| 2020 |
Dubbelman MA, Verrijp M, Facal D, Sánchez-Benavides G, Brown LJE, van der Flier WM, Jokinen H, Lee A, Leroi I, Lojo-Seoane C, Milošević V, Molinuevo JL, Pereiro Rozas AX, Ritchie C, Salloway S, ... ... Scheltens P, et al. The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12021. PMID 32420446 DOI: 10.1002/Dad2.12021 |
0.307 |
|
| 2020 |
Wolters EE, Ossenkoppele R, Verfaillie SCJ, Coomans EM, Timmers T, Visser D, Tuncel H, Golla SSV, Windhorst AD, Boellaard R, van der Flier WM, Teunissen CE, Scheltens P, van Berckel BNM. Correction to: Regional [F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging. PMID 32388611 DOI: 10.1007/S00259-020-04849-0 |
0.393 |
|
| 2020 |
Jutten RJ, Harrison JE, Brunner AJ, Vreeswijk R, van Deelen RAJ, de Jong FJ, Opmeer EM, Ritchie CW, Aleman A, Scheltens P, Sikkes SAM. The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. Alzheimer's & Dementia (New York, N. Y.). 6: e12020. PMID 32313832 DOI: 10.1002/Trc2.12020 |
0.404 |
|
| 2020 |
Reus LM, Stringer S, Posthuma D, Teunissen CE, Scheltens P, Pijnenburg YAL, Visser PJ, Tijms BM. Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. Neurobiology of Aging. PMID 32307133 DOI: 10.1016/J.Neurobiolaging.2020.03.012 |
0.42 |
|
| 2020 |
Wolters EE, Ossenkoppele R, Verfaillie SCJ, Coomans EM, Timmers T, Visser D, Tuncel H, Golla SSV, Windhorst AD, Boellaard R, van der Flier WM, Teunissen CE, Scheltens P, van Berckel BNM. Regional [F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging. PMID 32291510 DOI: 10.1007/S00259-020-04758-2 |
0.409 |
|
| 2020 |
Lopes Alves I, Collij LE, Altomare D, Frisoni GB, Saint-Aubert L, Payoux P, Kivipelto M, Jessen F, Drzezga A, Leeuwis A, Wink AM, Visser PJ, van Berckel BNM, Scheltens P, Gray KR, et al. Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32281303 DOI: 10.1002/Alz.12069 |
0.525 |
|
| 2020 |
Pitkänen J, Koikkalainen J, Nieminen T, Marinkovic I, Curtze S, Sibolt G, Jokinen H, Rueckert D, Barkhof F, Schmidt R, Pantoni L, Scheltens P, Wahlund LO, Korvenoja A, Lötjönen J, et al. Evaluating severity of white matter lesions from computed tomography images with convolutional neural network. Neuroradiology. PMID 32281028 DOI: 10.1007/S00234-020-02410-2 |
0.375 |
|
| 2020 |
Boelaarts L, de Jonghe JFM, Scheltens P. Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited. Dementia and Geriatric Cognitive Disorders. 1-6. PMID 32224618 DOI: 10.1159/000506332 |
0.383 |
|
| 2020 |
Kleineidam L, Chouraki V, Próchnicki T, van der Lee SJ, Madrid-Márquez L, Wagner-Thelen H, Karaca I, Weinhold L, Wolfsgruber S, Boland A, Martino Adami PV, Lewczuk P, Popp J, Brosseron F, Jansen IE, ... ... Scheltens P, et al. PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica. PMID 32166339 DOI: 10.1007/S00401-020-02138-6 |
0.483 |
|
| 2020 |
Fieldhouse JLP, Doorduijn AS, de Leeuw FA, Verhaar BJH, Koene T, Wesselman LMP, Schueren MV, Visser M, Rest OV, Scheltens P, Kester MI, Flier WMV. A Suboptimal Diet is Associated with Poorer Cognition: The NUDAD Project. Nutrients. 12. PMID 32155876 DOI: 10.3390/Nu12030703 |
0.449 |
|
| 2020 |
Trieu C, Gossink F, Stek ML, Scheltens P, Pijnenburg YAL, Dols A. Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic Review. Cognitive and Behavioral Neurology : Official Journal of the Society For Behavioral and Cognitive Neurology. 33: 1-15. PMID 32132398 DOI: 10.1097/Wnn.0000000000000217 |
0.309 |
|
| 2020 |
Vignoli A, Paciotti S, Tenori L, Eusebi P, Biscetti L, Chiasserini D, Scheltens P, Turano P, Teunissen C, Luchinat C, Parnetti L. Fingerprinting Alzheimer's Disease by H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. Journal of Proteome Research. PMID 32118444 DOI: 10.1021/Acs.Jproteome.9B00850 |
0.467 |
|
| 2020 |
Verberk IMW, Hendriksen HMA, van Harten AC, Wesselman LMP, Verfaillie SCJ, van den Bosch KA, Slot RER, Prins ND, Scheltens P, Teunissen CE, Van der Flier WM. Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging. PMID 32081465 DOI: 10.1016/J.Neurobiolaging.2020.01.007 |
0.405 |
|
| 2020 |
de Leeuw FA, van der Flier WM, Tijms BM, Scheltens P, Mendes VM, Manadas B, Bierau J, van Wijk N, van den Heuvel EGHM, Mohajeri MH, Teunissen CE, Kester MI. Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. Journal of the American Medical Directors Association. PMID 32001171 DOI: 10.1016/J.Jamda.2019.12.009 |
0.393 |
|
| 2020 |
Westwood S, Baird AL, Anand SN, Nevado-Holgado AJ, Kormilitzin A, Shi L, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Baker S, Buckley NJ, Ten Kate M, Scheltens P, et al. Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease : Jad. PMID 31985466 DOI: 10.3233/Jad-190434 |
0.539 |
|
| 2020 |
Rhodius-Meester HFM, van Maurik IS, Koikkalainen J, Tolonen A, Frederiksen KS, Hasselbalch SG, Soininen H, Herukka SK, Remes AM, Teunissen CE, Barkhof F, Pijnenburg YAL, Scheltens P, Lötjönen J, van der Flier WM. Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. Plos One. 15: e0226784. PMID 31940390 DOI: 10.1371/Journal.Pone.0226784 |
0.493 |
|
| 2020 |
Leijenaar JF, Groeneveld GJ, Klaassen ES, Leeuwis AE, Scheltens P, Weinstein HC, van Gerven JMA, Barkhof F, van der Flier WM, Prins ND. Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI. Alzheimer's Research & Therapy. 12: 10. PMID 31910895 DOI: 10.1186/S13195-019-0567-Z |
0.46 |
|
| 2020 |
Vermunt L, Muniz-Terrera G, Ter Meulen L, Veal C, Blennow K, Campbell A, Carrié I, Delrieu J, Fauria K, Huesa Rodríguez G, Ingala S, Jenkins N, Molinuevo JL, Ousset PJ, Porteous D, ... ... Scheltens P, et al. Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimer's Research & Therapy. 12: 8. PMID 31907067 DOI: 10.1186/S13195-019-0576-Y |
0.426 |
|
| 2020 |
Vignoli A, Paciotti S, Tenori L, Eusebi P, Biscetti L, Chiasserini D, Scheltens P, Turano P, Teunissen C, Luchinat C, Parnetti L. FingerprintingAlzheimer’s Diseaseby 1H Nuclear Magnetic ResonanceSpectroscopy of Cerebrospinal Fluid Journal of Proteome Research. DOI: 10.1021/Acs.Jproteome.9B00850.S001 |
0.416 |
|
| 2019 |
Boon BDC, Pouwels PJW, Jonkman LE, Keijzer MJ, Preziosa P, van de Berg WDJ, Geurts JJG, Scheltens P, Barkhof F, Rozemuller AJM, Bouwman FH, Steenwijk MD. Can MRI be used as a proxy for ? A case study. Brain Communications. 1: fcz030. PMID 32954270 DOI: 10.1093/braincomms/fcz030 |
0.355 |
|
| 2019 |
Stamate D, Kim M, Proitsi P, Westwood S, Baird A, Nevado-Holgado A, Hye A, Bos I, Vos SJB, Vandenberghe R, Teunissen CE, Kate MT, Scheltens P, Gabel S, Meersmans K, et al. A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's & Dementia (New York, N. Y.). 5: 933-938. PMID 31890857 DOI: 10.1016/J.Trci.2019.11.001 |
0.397 |
|
| 2019 |
Wolters EE, Ossenkoppele R, Golla SS, Verfaillie SC, Timmers T, Visser D, Tuncel H, Coomans EM, Windhorst AD, Scheltens P, van der Flier WM, Boellaard R, van Berckel BN. Hippocampal [F]flortaucipir BP corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. Neuroimage. Clinical. 25: 102113. PMID 31835238 DOI: 10.1016/J.Nicl.2019.102113 |
0.312 |
|
| 2019 |
Reimand J, de Wilde A, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, Barkhof F, van der Flier WM, Scheltens P, van Berckel BNM, Ossenkoppele R, Bouwman F. PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases. Alzheimer's Research & Therapy. 11: 100. PMID 31810489 DOI: 10.1186/S13195-019-0561-5 |
0.453 |
|
| 2019 |
Reimand J, Groot C, Teunissen CE, Windhorst AD, Boellaard R, Barkhof F, Nazarenko S, van der Flier WM, van Berckel BNM, Scheltens P, Ossenkoppele R, Bouwman F. Why Is Amyloid-β PET Requested After Performing Cerebrospinal Fluid Biomarkers? Journal of Alzheimer's Disease : Jad. PMID 31796674 DOI: 10.3233/Jad-190836 |
0.467 |
|
| 2019 |
Leijenaar JF, Groot C, Sudre CH, Bergeron D, Leeuwis AE, Cardoso MJ, Carrasco FP, Laforce R, Barkhof F, van der Flier WM, Scheltens P, Prins ND, Ossenkoppele R. Comorbid amyloid-β pathology affects clinical and imaging features in VCD. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31786129 DOI: 10.1016/J.Jalz.2019.08.190 |
0.469 |
|
| 2019 |
Jokinen H, Koikkalainen J, Laakso HM, Melkas S, Nieminen T, Brander A, Korvenoja A, Rueckert D, Barkhof F, Scheltens P, Schmidt R, Fazekas F, Madureira S, Verdelho A, Wallin A, et al. Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. Stroke. STROKEAHA119026170. PMID 31699021 DOI: 10.1161/Strokeaha.119.026170 |
0.425 |
|
| 2019 |
Scheltens NME, Briels CT, Yaqub M, Barkhof F, Boellaard R, van der Flier WM, Schwarte LA, Teunissen CE, Attali A, Broersen LM, van Berckel BNM, Scheltens P. Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 5: 492-500. PMID 31650005 DOI: 10.1016/J.Trci.2019.08.002 |
0.47 |
|
| 2019 |
Banning LCP, Janssen EPCJ, Hamel REG, de Vugt M, Köhler S, Wolfs CAG, Oosterveld SM, Melis RJF, Olde Rikkert MGM, Kessels RPC, Pijnenburg YAL, Koene T, van der Flier WM, Scheltens P, Visser PJ, et al. Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia. Journal of Geriatric Psychiatry and Neurology. 891988719882104. PMID 31645191 DOI: 10.1177/0891988719882104 |
0.33 |
|
| 2019 |
van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimer's Research & Therapy. 11: 83. PMID 31601267 DOI: 10.1186/S13195-019-0537-5 |
0.435 |
|
| 2019 |
Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, van Berckel BN, Teunissen CE, Frisoni GB, Scheltens P, van der Flier WM. Applying the ATN scheme in a memory clinic population: The ABIDE project. Neurology. PMID 31597710 DOI: 10.1212/Wnl.0000000000008361 |
0.382 |
|
| 2019 |
de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, Lammertsma AA, Biessels GJ, Scheltens P, van Berckel BN, van der Flier WM. Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31594684 DOI: 10.1016/J.Jalz.2019.07.003 |
0.43 |
|
| 2019 |
Frisoni GB, Ritchie C, Carrera E, Nilsson P, Ousset PJ, Molinuevo JL, Dubois B, Scheltens P, Minoshima S. Re-aligning scientific and lay narratives of Alzheimer's disease. The Lancet. Neurology. 18: 918-919. PMID 31526751 DOI: 10.1016/S1474-4422(19)30323-0 |
0.403 |
|
| 2019 |
van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Frisoni GB, et al. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. The Lancet. Neurology. PMID 31526625 DOI: 10.1016/S1474-4422(19)30283-2 |
0.506 |
|
| 2019 |
de Wilde A, Reimand J, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, van der Flier WM, Scheltens P, van Berckel BNM, Bouwman F, Ossenkoppele R. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences. Alzheimer's Research & Therapy. 11: 78. PMID 31511058 DOI: 10.1186/S13195-019-0532-X |
0.337 |
|
| 2019 |
Weaver NA, Doeven T, Barkhof F, Biesbroek JM, Groeneveld ON, Kuijf HJ, Prins ND, Scheltens P, Teunissen CE, van der Flier WM, Biessels GJ. Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. Neurobiology of Aging. PMID 31500909 DOI: 10.1016/J.Neurobiolaging.2019.08.001 |
0.525 |
|
| 2019 |
Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F, Hong S, Franke A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Buckley NJ, Kate MT, ... Scheltens P, et al. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31495601 DOI: 10.1016/J.Jalz.2019.06.4951 |
0.454 |
|
| 2019 |
Cummings J, Feldman HH, Scheltens P. The "rights" of precision drug development for Alzheimer's disease. Alzheimer's Research & Therapy. 11: 76. PMID 31470905 DOI: 10.1186/S13195-019-0529-5 |
0.333 |
|
| 2019 |
Bertens D, Vos S, Kehoe P, Wolf H, Nobili F, Mendonça A, van Rossum I, Hort J, Molinuevo JL, Heneka M, Petersen R, Scheltens P, Visser PJ. Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. Alzheimer's Research & Therapy. 11: 74. PMID 31439020 DOI: 10.1186/S13195-019-0525-9 |
0.473 |
|
| 2019 |
Hijazi S, Heistek TS, Scheltens P, Neumann U, Shimshek DR, Mansvelder HD, Smit AB, van Kesteren RE. Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer's disease. Molecular Psychiatry. PMID 31431685 DOI: 10.1038/S41380-019-0483-4 |
0.363 |
|
| 2019 |
Dauwan M, Begemann MJH, Slot MIE, Lee EHM, Scheltens P, Sommer IEC. Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials. Journal of Neurology. PMID 31414194 DOI: 10.1007/S00415-019-09493-9 |
0.301 |
|
| 2019 |
Legdeur N, Tijms BM, Konijnenberg E, den Braber A, Ten Kate M, Sudre CH, Tomassen J, Badissi M, Yaqub M, Barkhof F, van Berckel BN, Boomsma DI, Scheltens P, Holstege H, Maier AB, et al. Associations of brain pathology, cognitive and physical markers with age in cognitively normal individuals aged 60-102 years. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. PMID 31411322 DOI: 10.1093/Gerona/Glz180 |
0.488 |
|
| 2019 |
van Maurik IS, van der Kall LM, de Wilde A, Bouwman FH, Scheltens P, van Berckel BNM, Berkhof J, van der Flier WM. Added value of amyloid PET in individualized risk predictions for MCI patients. Alzheimer's & Dementia (Amsterdam, Netherlands). 11: 529-537. PMID 31388557 DOI: 10.1016/J.Dadm.2019.04.011 |
0.405 |
|
| 2019 |
Verwey NA, Teunissen CE, Hoozemans JJM, Rozemuller AJM, Scheltens P, Pijnenburg YAL. Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study. Journal of Alzheimer's Disease : Jad. PMID 31356209 DOI: 10.3233/Jad-190344 |
0.414 |
|
| 2019 |
den Haan J, Csinscik L, Parker T, Paterson RW, Slattery CF, Foulkes A, Bouwman FH, Verbraak FD, Scheltens P, Peto T, Lengyel I, Schott JM, Crutch SJ, Shakespeare TJ, Yong KXX. Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's disease. Alzheimer's Research & Therapy. 11: 62. PMID 31319885 DOI: 10.1186/S13195-019-0516-X |
0.396 |
|
| 2019 |
Wang Y, Haaksma ML, Ramakers IHGB, Verhey FRJ, van de Flier WM, Scheltens P, van Maurik I, Olde Rikkert MGM, Leoutsakos JS, Melis RJF. Cognitive and functional progression of dementia in two longitudinal studies. International Journal of Geriatric Psychiatry. PMID 31318090 DOI: 10.1002/Gps.5175 |
0.433 |
|
| 2019 |
van Maurik IS, Visser LN, Pel-Littel RE, van Buchem MM, Zwan MD, Kunneman M, Pelkmans W, Bouwman FH, Minkman M, Schoonenboom N, Scheltens P, Smets EM, van der Flier WM. Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. Jmir Formative Research. 3: e13417. PMID 31287061 DOI: 10.2196/13417 |
0.308 |
|
| 2019 |
Boelaarts L, Meyer SRA, Scheltens P, de Jonghe JFM. Testing Episodic Memory in Elderly Subjects: Not as Simple as It Looks. Dementia and Geriatric Cognitive Disorders Extra. 9: 207-216. PMID 31275346 DOI: 10.1159/000499836 |
0.387 |
|
| 2019 |
Timmers T, Ossenkoppele R, Wolters EE, Verfaillie SCJ, Visser D, Golla SSV, Barkhof F, Scheltens P, Boellaard R, van der Flier WM, van Berckel BNM. Associations between quantitative [F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum. Alzheimer's Research & Therapy. 11: 60. PMID 31272512 DOI: 10.1186/S13195-019-0510-3 |
0.5 |
|
| 2019 |
Altomare D, Ferrari C, Caroli A, Galluzzi S, Prestia A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall A, Carter SF, Schöll M, Choo ILH, Grimmer T, ... ... Scheltens P, et al. Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology. PMID 31267207 DOI: 10.1007/S00415-019-09441-7 |
0.528 |
|
| 2019 |
van Loenhoud AC, van der Flier WM, Wink AM, Dicks E, Groot C, Twisk J, Barkhof F, Scheltens P, Ossenkoppele R. Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship. Neurology. PMID 31266904 DOI: 10.1212/Wnl.0000000000007821 |
0.554 |
|
| 2019 |
Haan JD, van de Kreeke JA, Konijnenberg E, Kate MT, Braber AD, Barkhof F, van Berckel BN, Teunissen CE, Scheltens P, Visser PJ, Verbraak FD, Bouwman FH. Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 11: 463-471. PMID 31249859 DOI: 10.1016/J.Dadm.2019.05.002 |
0.501 |
|
| 2019 |
Haan JD, van de Kreeke JA, van Berckel BN, Barkhof F, Teunissen CE, Scheltens P, Verbraak FD, Bouwman FH. Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease? Alzheimer's & Dementia (Amsterdam, Netherlands). 11: 383-391. PMID 31193094 DOI: 10.1016/J.Dadm.2019.03.006 |
0.517 |
|
| 2019 |
Legdeur N, Visser PJ, Woodworth DC, Muller M, Fletcher E, Maillard P, Scheltens P, DeCarli C, Kawas CH, Corrada MM. White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study. Journal of the American Geriatrics Society. PMID 31169919 DOI: 10.1111/Jgs.15990 |
0.359 |
|
| 2019 |
Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, Kern S, Ousset PJ, Maruff P, Skoog I, Verhey FRJ, Freund-Levi Y, Tsolaki M, Wallin ÅK, Olde Rikkert M, ... ... Scheltens P, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31164314 DOI: 10.1016/J.Jalz.2019.04.001 |
0.441 |
|
| 2019 |
Pelkmans W, Dicks E, Barkhof F, Vrenken H, Scheltens P, van der Flier WM, Tijms BM. Gray matter T1-w/T2-w ratios are higher in Alzheimer's disease. Human Brain Mapping. PMID 31157938 DOI: 10.1002/Hbm.24638 |
0.462 |
|
| 2019 |
van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, ... ... Scheltens P, et al. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica. PMID 31131421 DOI: 10.1007/S00401-019-02026-8 |
0.389 |
|
| 2019 |
Doorduijn AS, Visser M, van de Rest O, Kester MI, de Leeuw FA, Boesveldt S, Fieldhouse JLP, van den Heuvel EGHM, Teunissen CE, Scheltens P, van der Flier WM, de van der Schueren MAE. Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. Nutrients. 11. PMID 31126170 DOI: 10.3390/Nu11051161 |
0.445 |
|
| 2019 |
Eikelboom WS, Singleton E, van den Berg E, Coesmans M, Mattace Raso F, van Bruchem RL, Goudzwaard JA, de Jong FJ, Koopmanschap M, den Heijer T, Driesen JJM, Vroegindeweij LJHM, Thomeer EC, Hoogers SE, Dijkstra AA, ... ... Scheltens P, et al. Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study. Alzheimer's Research & Therapy. 11: 48. PMID 31122267 DOI: 10.1186/S13195-019-0503-2 |
0.412 |
|
| 2019 |
Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P, Scheltens P, Poirier J, Saftig P, Bateman RJ, Breitner J, et al. Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. Nature Communications. 10: 2240. PMID 31110178 DOI: 10.1038/S41467-019-10152-W |
0.451 |
|
| 2019 |
Jutten RJ, Harrison JE, Lee Meeuw Kjoe PR, Ingala S, Vreeswijk R, van Deelen RAJ, de Jong FJ, Opmeer EM, Aleman A, Ritchie CW, Scheltens P, Sikkes SAM. Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. Alzheimer's Research & Therapy. 11: 45. PMID 31092277 DOI: 10.1186/S13195-019-0500-5 |
0.386 |
|
| 2019 |
Wesselman LMP, Doorduijn AS, de Leeuw FA, Verfaillie SCJ, van Leeuwenstijn-Koopman M, Slot RER, Kester MI, Prins ND, van de Rest O, de van der Schueren MAE, Scheltens P, Sikkes SAM, van der Flier WM. Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project. Nutrients. 11. PMID 31083522 DOI: 10.3390/Nu11051057 |
0.346 |
|
| 2019 |
Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, Westwood S, Baird A, Proitsi P, Nevado-Holgado A, Hye A, Bos I, Vos S, Vandenberghe R, Teunissen C, ... ... Scheltens P, et al. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31078433 DOI: 10.1016/J.Jalz.2019.03.004 |
0.539 |
|
| 2019 |
Verfaillie SCJ, Witteman J, Slot RER, Pruis I, Vermaat LEW, Prins ND, Schiller NO, van de Wiel M, Scheltens P, van Berckel BNM, van der Flier WM, Sikkes SAM. High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. Neuropsychologia. PMID 31075283 DOI: 10.1016/J.Neuropsychologia.2019.05.006 |
0.387 |
|
| 2019 |
Vermunt L, van Paasen AJL, Teunissen CE, Scheltens P, Visser PJ, Tijms BM. Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. Neurology. PMID 31068481 DOI: 10.1212/Wnl.0000000000007609 |
0.428 |
|
| 2019 |
Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ, Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, ... ... Scheltens P, et al. Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31047856 DOI: 10.1016/J.Jalz.2019.03.007 |
0.494 |
|
| 2019 |
Fuermaier ABM, Piersma D, de Waard D, Davidse RJ, de Groot J, Doumen MJA, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, De Deyn PP, Brouwer WH, et al. Driving Difficulties Among Patients with Alzheimer's Disease and Other Neurodegenerative Disorders. Journal of Alzheimer's Disease : Jad. PMID 31045516 DOI: 10.3233/Jad-181095 |
0.37 |
|
| 2019 |
Slot RER, Kester MI, Van Harten AC, Jongbloed W, Bouwman FH, Teunissen CE, Scheltens P, van der Flier WM, Veerhuis R. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly. Neurobiology of Aging. 79: 101-109. PMID 31029938 DOI: 10.1016/J.Neurobiolaging.2019.02.017 |
0.431 |
|
| 2019 |
Timmers T, Ossenkoppele R, Verfaillie SCJ, van der Weijden CWJ, Slot RER, Wesselman LMP, Windhorst AD, Wolters EE, Yaqub M, Prins ND, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BNM. Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project. Neurobiology of Aging. 79: 50-58. PMID 31026622 DOI: 10.1016/J.Neurobiolaging.2019.02.020 |
0.312 |
|
| 2019 |
Leeuwis AE, Weaver NA, Biesbroek JM, Exalto LG, Kuijf HJ, Hooghiemstra AM, Prins ND, Scheltens P, Barkhof F, van der Flier WM, Biessels GJ. Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion–symptom mapping study Journal of Psychiatry & Neuroscience : Jpn. 44: 1-10. PMID 31021068 DOI: 10.1503/Jpn.180136 |
0.369 |
|
| 2019 |
van Maurik IS, Slot RER, Verfaillie SCJ, Zwan MD, Bouwman FH, Prins ND, Teunissen CE, Scheltens P, Barkhof F, Wattjes MP, Molinuevo JL, Rami L, Wolfsgruber S, Peters O, Jessen F, et al. Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. Alzheimer's Research & Therapy. 11: 33. PMID 30987684 DOI: 10.1186/S13195-019-0487-Y |
0.524 |
|
| 2019 |
Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, et al. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30967340 DOI: 10.1016/J.Jalz.2019.01.015 |
0.425 |
|
| 2019 |
Dicks E, Vermunt L, van der Flier WM, Visser PJ, Barkhof F, Scheltens P, Tijms BM. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. Neuroimage. Clinical. 22: 101786. PMID 30921610 DOI: 10.1016/J.Nicl.2019.101786 |
0.539 |
|
| 2019 |
Boomsma JMF, Exalto LG, Barkhof F, Berg EVD, Bresser J, Heinen R, Leeuwis AE, Prins ND, Scheltens P, Weinstein HC, van der Flier WM, Biessels GJ. How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. Journal of Alzheimer's Disease : Jad. PMID 30909212 DOI: 10.3233/Jad-180696 |
0.504 |
|
| 2019 |
Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S, Sleegers K, Frisoni G, Blin O, Richardson JC, Bordet R, Tsolaki M, Popp J, Peyratout G, Martinez-Lage P, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30853464 DOI: 10.1016/J.Jalz.2019.01.004 |
0.517 |
|
| 2019 |
Koikkalainen JR, Rhodius-Meester HFM, Frederiksen KS, Bruun M, Hasselbalch SG, Baroni M, Mecocci P, Vanninen R, Remes A, Soininen H, van Gils M, van der Flier WM, Scheltens P, Barkhof F, Erkinjuntti T, et al. Automatically computed rating scales from MRI for patients with cognitive disorders. European Radiology. PMID 30796570 DOI: 10.1007/S00330-019-06067-1 |
0.422 |
|
| 2019 |
Konijnenberg E, den Braber A, Ten Kate M, Tomassen J, Mulder SD, Yaqub M, Teunissen CE, Lammertsma AA, van Berckel BNM, Scheltens P, Boomsma DI, Visser PJ. Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. Neurobiology of Aging. 77: 58-65. PMID 30784813 DOI: 10.1016/J.Neurobiolaging.2019.01.006 |
0.395 |
|
| 2019 |
Groeneveld ON, Moneti C, Heinen R, de Bresser J, Kuijf HJ, Exalto LG, Boomsma JMF, Kappelle LJ, Barkhof F, Prins ND, Scheltens P, van der Flier WM, Biessels GJ. The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. Journal of Alzheimer's Disease : Jad. PMID 30775988 DOI: 10.3233/Jad-180914 |
0.479 |
|
| 2019 |
Verfaillie SCJ, Timmers T, Slot RER, van der Weijden CWJ, Wesselman LMP, Prins ND, Sikkes SAM, Yaqub M, Dols A, Lammertsma AA, Scheltens P, Ossenkoppele R, van Berckel BNM, van der Flier WM. Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project. Frontiers in Aging Neuroscience. 11: 7. PMID 30760996 DOI: 10.3389/Fnagi.2019.00007 |
0.376 |
|
| 2019 |
Jagust W, Jack CR, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, et al. "Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia". Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 15: 153-157. PMID 30642435 DOI: 10.1016/J.Jalz.2018.11.002 |
0.443 |
|
| 2019 |
Babapour Mofrad R, Schoonenboom NSM, Tijms BM, Scheltens P, Visser PJ, van der Flier WM, Teunissen CE. Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 11: 1-9. PMID 30569013 DOI: 10.1016/J.Dadm.2018.10.004 |
0.405 |
|
| 2019 |
Visser PJ, Gobom J, Reus LM, Jansen IE, Tsolaki M, Verhey FRJ, Popp J, Martinez-Lage P, Vandenberghe R, Lleó A, Molinuevo JL, Engelborghs S, Lovestone S, Streffer J, Vos SJB, ... ... Scheltens P, et al. P4-525: Association Of Csf Tau With Hyperplasticity In Alzheimer'S Disease Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.08.072 |
0.377 |
|
| 2019 |
Lötjönen J, Koikkalainen J, Meester HFMR, Baroni M, Mecocci P, Remes A, Soininen H, Erkinjuntti T, Teunissen CE, Scheltens P, Barkhof F, Flier WMvd, Law I, Hasselbalch SG, Frederiksen KS. P1‐347: Detecting Alzheimer'S Disease At Different Levels Of White‐Matter Hyperintensities Using Mri Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.902 |
0.496 |
|
| 2019 |
Singleton EH, Pijnenburg YAL, Sudre CH, Kochova E, Groot C, Papma JM, Swieten JCv, Barkhof F, Scheltens P, Rabinovici GD, Ossenkoppele R. Ic-P-097: Differentiating The Behavioural Variant Of Alzheimer'S Disease From Behavioural Variant Frontotemporal Dementia And Typical Alzheimer'S Disease: The Value Of Neuroimaging Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4940 |
0.519 |
|
| 2019 |
Bos I, Vos SJB, Kate Mt, Jansen WJ, Scheltens P, Engelborghs S, Frisoni GB, Blin O, Richardson J, Bordet R, Tsolaki M, Verhey FRJ, Popp J, Martinez-Lage P, Vandenberghe R, et al. Associations Between Cerebrospinal Fluid Neurodegenerative Markers, Neurofilament-Light And Total Tau And Cerebrovascular Imaging Markers Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4860 |
0.404 |
|
| 2019 |
Timmers T, Ossenkoppele R, Verfaillie SCJ, Wolters EE, Visser D, Scheltens P, Schmidt ME, Boellaard R, Golla SSV, Flier WMvd, Berckel BNMV. Early Tau Pet Pathology Is Associated With Memory Performance In Cognitively Unimpaired Individuals With Scd: The Science Project Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4836 |
0.333 |
|
| 2019 |
Loenhoud ACv, Groot C, Barkhof F, Scheltens P, Flier WMvd, Ossenkoppele R. Ic-P-100: A Longitudinal Study Of The Effects Of Education And Intracranial Volume On Cognitive Changes And Mortality Rates In Alzheimer'S Disease Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4766 |
0.489 |
|
| 2019 |
Leijenaar JF, Groot C, Sudre CH, Bergeron D, Leeuwis AE, Cardoso J, Carrasco FP, Laforce R, Barkhof F, Flier WMvd, Scheltens P, Prins ND, Ossenkoppele R. COMORBID AMYLOID-β PATHOLOGY AFFECTS NEUROPSYCHIATRIC, NEUROPSYCHOLOGICAL, AND IMAGING FEATURES IN VASCULAR COGNITIVE DISORDERS Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4647 |
0.455 |
|
| 2019 |
Salvadó G, Ferreira D, Cacciaglia R, Operto G, Falcon C, Groot C, Flier WMvd, Barkhof F, Scheltens P, Ossenkoppele R, Stomrud E, Westen Dv, Hansson O, Molinuevo JL, Wahlund L, et al. O3-02-06: COGNITIVELY NORMAL APOE-ε2 HOMOZYGOTES DISPLAY GREATER HIPPOCAMPI: AN UNBIASED VOXEL-BASED ANALYSIS Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4635 |
0.446 |
|
| 2019 |
Scheltens P. F3-01-01: The Diagnostic Framework For Alzheimer'S Disease Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4596 |
0.333 |
|
| 2019 |
Eikelboom WS, Berg Evd, Coesmans M, Singleton EH, Swieten JCv, Pijnenburg YAL, Scheltens P, Flier WMvd, Ossenkoppele R, Papma JM. O2-11-02: Neuropsychiatric And Cognitive Symptoms In Alzheimer'S Disease: A Study In Ad Biomarker Confirmed Patients Across The Clinical Spectrum Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4512 |
0.424 |
|
| 2019 |
Meester HFR, Maurik ISV, Koikkalainen J, Barkhof F, Teunissen CE, Frederiksen KS, Scheltens P, Meccocci P, Baroni M, Remes A, Soininen H, Hasselbalch SG, Flier WMvd, Lötjönen J. O2-02-03: Stepwise Patient Selection For Amyloid Measurements Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4459 |
0.387 |
|
| 2019 |
Verberk IMW, Thijssen E, Koelewijn AM, Scheltens P, Flier WMvd, Stoops E, Vanderstichele HM, Teunissen CE. F2-07-04: Plasma Amyloid Beta 1-42 And 1-40 Measured By A Novel Simoa Assay As A Diagnostic Tool For Alzheimer'S Disease Pathology Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4443 |
0.321 |
|
| 2019 |
Jutten RJ, Sikkes SAM, Amariglio R, Buckley RF, Properzi MJ, Marshall GA, Rentz DM, Johnson KA, Flier WMvd, Scheltens P, Sperling RA, Papp KV. F2-03-02: Optimizing Cognitive Outcomes For Biomarker Positive Individuals At Different Clinical Stages Of Alzheimer'S Disease According To The Nia-Aa Research Framework Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4425 |
0.354 |
|
| 2019 |
Miller ZA, Ossenkoppele R, Shwe W, Allen IE, Rosenberg LM, Olguin D, Edwards K, Ketelle R, Karydas AM, Perry DC, Sturm V, Yokoyama JS, Desikan RS, Geschwind DH, Wolters EE, ... ... Scheltens P, et al. F2-01-01: Neurodevelopmental Differences And Environmental Insults Inversely Correlate With Age Of Onset In Alzheimer'S Disease Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4416 |
0.337 |
|
| 2019 |
Ebenau J, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, Teunissen CE, Barkhof F, Bosch Kvd, Leeuwenstijn Mv, Prins ND, Sikkes SAM, Scheltens P, Berckel BNMV, Flier WMvd. Atn Biomarker Model As A Determinant Of Cognitive Decline And Incident Clinical Progression In Subjective Cognitive Decline: The Science Project Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4383 |
0.47 |
|
| 2019 |
Maurik ISV, Visser LNC, Pel-Littel R, Buchem Mv, Zwan MD, Kunneman M, Pelkmans W, Bouwman FH, Minkman M, Schoonenboom NSM, Scheltens P, Smets EM, Flier WMvd. Development And Usability Of Adappt: An Online Tool To Support Clinicians, Patients And Caregivers In The Diagnosis Of Mild Cognitive Impairment And Alzheimer’S Disease Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4336 |
0.387 |
|
| 2019 |
Dicks E, van der Flier WM, Barkhof F, Scheltens P, Tijms BM. IC-02-01: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE Alzheimer's & Dementia. 15: P1-P1. DOI: 10.1016/J.Jalz.2019.06.4145 |
0.524 |
|
| 2019 |
Visser D, Ossenkoppele R, Verfaillie SCJ, Timmers T, Wolters EE, Tuncel H, Coomans E, Schmidt ME, Boellaard R, Windhorst AD, Scheltens P, Flier WMvd, Berckel BNMV. P4-316: Longitudinal Dynamic [18F]Flortaucipir Pet Reveals Increased Early Stage Tau Pathology In Individuals With Subjective Cognitive Decline Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.3986 |
0.33 |
|
| 2019 |
Leeuw FAd, Doorduijn A, Fieldhouse JLP, Schueren Mdvd, Rest Ovd, Heuvel EGHMvd, Scheltens P, Teunissen CE, Kester MI, Flier WMvd. P3-607: Dietary Intake And Nutrient Levels Of B-Vitamins And Omega-3 Fatty Acids Are Differentially Associated In Subjective Cognitive Decline, Mild Cognitive Impairment And Alzheimer'S Disease: The Nudad Project Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.3645 |
0.357 |
|
| 2019 |
Groot C, Risacher SL, Chen JA, Saykin AJ, MacDonald C, Mez J, Trittschuh EH, Mukherjee S, Gibbons LE, Choi S, Sanders RE, Dicks E, Barkhof F, Scheltens P, van der Flier WM, et al. P3-422: FDG-PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELY DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE Alzheimer's & Dementia. 15: P1119-P1120. DOI: 10.1016/J.Jalz.2019.06.3456 |
0.516 |
|
| 2019 |
Altomare D, Barkhof F, Berkhof J, Boccardi M, Canzoneri E, Collij L, Drzezga A, Farrar G, Garibotto V, Gismondi R, Gispert JD, Jessen F, Kivipelto M, Alves IL, Molinuevo JL, ... ... Scheltens P, et al. P3-373: Amypad-Dpms Preliminary Results: Participants’ Baseline Features Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.3406 |
0.346 |
|
| 2019 |
Jutten RJ, Harrison J, Vreeswijk R, Deelen BAJv, Opmeer EM, Aleman A, Jong FJd, Ritchie CW, Scheltens P, Sikkes SAM. P3-028: The Cognitive-Functional Composite Is Sensitive To Disease Progression In Mild Cognitive Impairment And Early Dementia: Longitudinal Findings From The Catch-Cog Study Cohort Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.3054 |
0.39 |
|
| 2019 |
Briels CT, Stam CJ, Scheltens P, Bruins S, Lues I, Gouw AA. P3-023: In Pursuit Of A Sensitive Eeg Functional Connectivity Outcome Measure For Clinical Trials In Alzheimer'S Disease Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.3049 |
0.335 |
|
| 2019 |
Wolters EE, Tuncel H, Golla SSV, Verfaillie SCJ, Berckel BNMV, Windhorst AD, Vries EFJd, Feltes PK, Glaudemans AWJM, Sweeney SP, Ryan JM, Ivarsson M, Lynch BA, Scheltens P, Deyn PPD, et al. P2-375: A Study To Evaluate The Kinetics And 28 Day Test-Retest Repeatability And Reproducibility Of The Radioligand [11C]Ucb-J For Brain Pet Imaging In Healthy Subjects And Mild-Moderate Alzheimer'S Disease Subjects Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.2782 |
0.343 |
|
| 2019 |
Handels R, Zwan MD, Pelkmans W, Bouwman FH, Biessels GJ, Roks G, Schoonenboom NSM, Verwey NA, Berckel BNMV, Flier WMvd, Verhey FRJ, Scheltens P. Added Diagnostic Value Of 18F-Flutemetamol Pet Scanning In Young Patients With Dementia Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.2772 |
0.371 |
|
| 2019 |
Legdeur N, Badissi M, Yaqub MM, Beker N, Sudre CH, Kate Mt, Gordon MF, Novak GP, Barkhof F, Berckel BNMV, Holstege H, Muller M, Scheltens P, Maier AB, Visser PJ. P2-345: What Determines Cognitive Functioning In The Oldest-Old? The Emif-Ad 90+ Study Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.2752 |
0.515 |
|
| 2019 |
Tijms BM, Gobom J, Blennow K, Tsolaki M, Verhey FRJ, Popp J, Martinez-Lage P, Vandenberghe R, Poesen K, Lleó A, Engelborghs S, Bertram L, Molinuevo JL, Lovestone S, Streffer J, ... ... Scheltens P, et al. P2-242: Pathophysiological Subtypes Of Alzheimer'S Disease Based On Cerebrospinal Fluid Proteomics Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.2649 |
0.359 |
|
| 2019 |
Briels CT, Scheltens NME, Yaqub MM, Barkhof F, Boellaard R, Flier WMvd, Schwarte LA, Teunissen CE, Broersen LM, Berckel BNMV, Scheltens P. P2-016: Exploring The Effect Of Souvenaid On Cerebral Glucose Metabolism In Early Alzheimer'S Disease Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.1238 |
0.457 |
|
| 2019 |
Fruijtier AD, Visser LNC, Maurik ISV, Scheltens P, Bouwman FH, Pijnenburg YAL, Ebenau J, Berckel BNMV, Smets EM, Flier WMvd. P1-424: An Rct To Identify Best Practices For Disclosure Of Amyloid Imaging Results In Mild Cognitive Impairment: The Abide Simulation-Study Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.1029 |
0.347 |
|
| 2019 |
Salvadó G, Collij L, Niñerola-Baizán A, Perissinotti A, Flier WMvd, Visser PJ, Scheltens P, Zetterberg H, Blennow K, Barkhof F, Molinuevo JL, Alves IL, Gispert JD, Study A, Adni. Ic-P-015: Voxel-Based Amyloid Pet Staging For The Whole Alzheimer'S Disease Continuum Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.1026 |
0.478 |
|
| 2019 |
Wolters EE, Ossenkoppele R, Verfaillie SCJ, Coomans E, Timmers T, Visser D, Tuncel H, Windhorst AD, Boellaard R, Flier WMvd, Teunissen CE, Scheltens P, Berckel BNMV. P1-412: [18F]Flortaucipir Binding Strongly Correlates To Cognition Across The Clinical Alzheimer'S Disease Continuum, Independently Of Csf Tau Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.1017 |
0.401 |
|
| 2019 |
de Haan W, Hillebrand A, Gouw A, Scheltens P, Stam K. P66-F Resting-state source-space MEG detects hippocampal hyperactivity in amyloid-positive amnestic MCI Clinical Neurophysiology. 130: e86. DOI: 10.1016/J.Clinph.2019.04.515 |
0.393 |
|
| 2018 |
Rhodius-Meester HFM, Liedes H, Koikkalainen J, Wolfsgruber S, Coll-Padros N, Kornhuber J, Peters O, Jessen F, Kleineidam L, Molinuevo JL, Rami L, Teunissen CE, Barkhof F, Sikkes SAM, Wesselman LMP, ... ... Scheltens P, et al. Computer-assisted prediction of clinical progression in the earliest stages of AD. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 726-736. PMID 30619929 DOI: 10.1016/J.Dadm.2018.09.001 |
0.494 |
|
| 2018 |
Westwood S, Baird AL, Hye A, Ashton NJ, Nevado-Holgado AJ, Anand SN, Liu B, Newby D, Bazenet C, Kiddle SJ, Ward M, Newton B, Desai K, Tan Hehir C, Zanette M, ... ... Scheltens P, et al. Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience. 10: 409. PMID 30618716 DOI: 10.3389/Fnagi.2018.00409 |
0.447 |
|
| 2018 |
den Haan J, Morrema THJ, Verbraak FD, de Boer JF, Scheltens P, Rozemuller AJ, Bergen AAB, Bouwman FH, Hoozemans JJ. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas. Acta Neuropathologica Communications. 6: 147. PMID 30593285 DOI: 10.1186/S40478-018-0650-X |
0.411 |
|
| 2018 |
Beker N, Sikkes SAM, Hulsman M, Schmand B, Scheltens P, Holstege H. Neuropsychological Test Performance of Cognitively Healthy Centenarians: Normative Data From the Dutch 100-Plus Study. Journal of the American Geriatrics Society. PMID 30592018 DOI: 10.1111/Jgs.15729 |
0.373 |
|
| 2018 |
Golla SS, Wolters EE, Timmers T, Ossenkoppele R, van der Weijden CW, Scheltens P, Schwarte L, Mintun MA, Devous MD, Schuit RC, Windhorst AD, Lammertsma AA, Yaqub M, van Berckel BN, Boellaard R. Parametric methods for [F]flortaucipir PET. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 271678X18820765. PMID 30569813 DOI: 10.1177/0271678X18820765 |
0.326 |
|
| 2018 |
Devi G, Scheltens P. Heterogeneity of Alzheimer's disease: consequence for drug trials? Alzheimer's Research & Therapy. 10: 122. PMID 30567585 DOI: 10.1186/S13195-018-0455-Y |
0.36 |
|
| 2018 |
Jutten RJ, Dicks E, Vermaat L, Barkhof F, Scheltens P, Tijms BM, Sikkes SAM. Impairment in complex activities of daily living is related to neurodegeneration in Alzheimer's disease-specific regions. Neurobiology of Aging. 75: 109-116. PMID 30557769 DOI: 10.1016/J.Neurobiolaging.2018.11.018 |
0.561 |
|
| 2018 |
Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, Dardiotis E, Guillo-Benarous F, Hampel H, Kochan NA, Lista S, Luck T, Maruff P, Molinuevo JL, Kornhuber J, ... ... Scheltens P, et al. Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30555032 DOI: 10.1016/J.Jalz.2018.10.003 |
0.506 |
|
| 2018 |
Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, Fagan AM, Hampel H, Mielke MM, Mikulskis A, O'Bryant S, Scheltens P, Sevigny J, Shaw LM, Soares HD, et al. Current state of Alzheimer's fluid biomarkers. Acta Neuropathologica. 136: 821-853. PMID 30488277 DOI: 10.1007/S00401-018-1932-X |
0.43 |
|
| 2018 |
Legdeur N, Badissi M, Carter SF, de Crom S, van de Kreeke A, Vreeswijk R, Trappenburg MC, Oudega ML, Koek HL, van Campen JP, Keijsers CJPW, Amadi C, Hinz R, Gordon MF, Novak G, ... ... Scheltens P, et al. Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. Bmc Geriatrics. 18: 289. PMID 30477432 DOI: 10.1186/S12877-018-0984-Z |
0.52 |
|
| 2018 |
Chakraborty A, Kamermans A, van Het Hof B, Castricum K, Aanhane E, van Horssen J, Thijssen VL, Scheltens P, Teunissen CE, Fontijn RD, van der Flier WM, de Vries HE. Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. Brain : a Journal of Neurology. PMID 30462206 DOI: 10.1093/Brain/Awy274 |
0.382 |
|
| 2018 |
Ten Kate M, Ingala S, Schwarz AJ, Fox NC, Chételat G, van Berckel BNM, Ewers M, Foley C, Gispert JD, Hill D, Irizarry MC, Lammertsma AA, Molinuevo JL, Ritchie C, Scheltens P, et al. Secondary prevention of Alzheimer's dementia: neuroimaging contributions. Alzheimer's Research & Therapy. 10: 112. PMID 30376881 DOI: 10.1186/S13195-018-0438-Z |
0.538 |
|
| 2018 |
Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. Human Brain Mapping. PMID 30368979 DOI: 10.1002/Hbm.24401 |
0.397 |
|
| 2018 |
Gossink FT, Vijverberg E, Krudop W, Scheltens P, Stek ML, Pijnenburg YAL, Dols A. Predicting progression in the late onset frontal lobe syndrome. International Psychogeriatrics. 1-6. PMID 30362933 DOI: 10.1017/S1041610218001242 |
0.344 |
|
| 2018 |
Holstege H, Beker N, Dijkstra T, Pieterse K, Wemmenhove E, Schouten K, Thiessens L, Horsten D, Rechtuijt S, Sikkes S, van Poppel FWA, Meijers-Heijboer H, Hulsman M, Scheltens P. The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. European Journal of Epidemiology. PMID 30362018 DOI: 10.1007/S10654-018-0451-3 |
0.379 |
|
| 2018 |
Ten Kate M, Dicks E, Visser PJ, van der Flier WM, Teunissen CE, Barkhof F, Scheltens P, Tijms BM. Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. Brain : a Journal of Neurology. PMID 30351346 DOI: 10.1093/Brain/Awy264 |
0.574 |
|
| 2018 |
Groot C, Sudre CH, Barkhof F, Teunissen CE, van Berckel BNM, Seo SW, Ourselin S, Scheltens P, Cardoso MJ, van der Flier WM, Ossenkoppele R. Clinical phenotype, atrophy, and small vessel disease in ε2 carriers with Alzheimer disease. Neurology. PMID 30341156 DOI: 10.1212/Wnl.0000000000006503 |
0.522 |
|
| 2018 |
Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, Collij L, Drzezga A, Farrar G, Garibotto V, Gismondi R, Gispert JD, Jessen F, Kivipelto M, Alves IL, ... ... Scheltens P, et al. AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30339801 DOI: 10.1016/J.Jalz.2018.09.003 |
0.47 |
|
| 2018 |
Bruun M, Rhodius-Meester HFM, Koikkalainen J, Baroni M, Gjerum L, Lemstra AW, Barkhof F, Remes AM, Urhemaa T, Tolonen A, Rueckert D, van Gils M, Frederiksen KS, Waldemar G, Scheltens P, et al. Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 509-518. PMID 30320203 DOI: 10.1016/J.Dadm.2018.07.003 |
0.434 |
|
| 2018 |
Collij L, Konijnenberg E, Reimand J, Ten Kate M, Den Braber A, Lopes Alves I, Zwan M, Yaqub M, Van Assema D, Wink AM, Lammertsma A, Scheltens P, Visser PJ, Barkhof F, Van Berckel B. Assessing Amyloid Pathology in Cognitively Normal Subjects using [F]Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30315145 DOI: 10.2967/Jnumed.118.211532 |
0.441 |
|
| 2018 |
Gardiner SL, Harder AVE, Campman YJM, Trompet S, Gussekloo J, van Belzen MJ, Boogaard MW, Roos RAC, Jansen IE, Pijnenburg YAL, Scheltens P, van der Flier WM, Aziz NA. Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease. Neurobiology of Aging. PMID 30314815 DOI: 10.1016/J.Neurobiolaging.2018.09.007 |
0.454 |
|
| 2018 |
Scheltens P, Hallikainen M, Grimmer T, Duning T, Gouw AA, Teunissen CE, Wink AM, Maruff P, Harrison J, van Baal CM, Bruins S, Lues I, Prins ND. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimer's Research & Therapy. 10: 107. PMID 30309389 DOI: 10.1186/S13195-018-0431-6 |
0.419 |
|
| 2018 |
Ten Kate M, Redolfi A, Peira E, Bos I, Vos SJ, Vandenberghe R, Gabel S, Schaeverbeke J, Scheltens P, Blin O, Richardson JC, Bordet R, Wallin A, Eckerstrom C, Molinuevo JL, et al. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research & Therapy. 10: 100. PMID 30261928 DOI: 10.1186/S13195-018-0428-1 |
0.553 |
|
| 2018 |
Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, et al. Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimer's Research & Therapy. 10: 99. PMID 30261916 DOI: 10.1186/S13195-018-0409-4 |
0.399 |
|
| 2018 |
Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, van Schoor N, Meijers-Heijboer H, Huisman M, Scheltens P, Reinders MJT, van der Flier WM, Holstege H. Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer's disease. European Journal of Human Genetics : Ejhg. PMID 30258121 DOI: 10.1038/S41431-018-0273-5 |
0.361 |
|
| 2018 |
Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, Pijnenburg Y, Keulen MA, Groot C, van Berckel BNM, van der Flier WM, Scheltens P, Rohrer JD, Warren JD, Schott JM, et al. Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Annals of Neurology. PMID 30255971 DOI: 10.1002/Ana.25333 |
0.334 |
|
| 2018 |
Tijms BM, Vermunt L, Zwan MD, van Harten AC, van der Flier WM, Teunissen CE, Scheltens P, Visser PJ. Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. Annals of Clinical and Translational Neurology. 5: 1037-1047. PMID 30250861 DOI: 10.1002/Acn3.615 |
0.466 |
|
| 2018 |
Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, Scheltens P, Teunissen CE, Van der Flier WM. Plasma amyloid as pre-screener for the earliest Alzheimer's pathological changes. Annals of Neurology. PMID 30196548 DOI: 10.1002/Ana.25334 |
0.42 |
|
| 2018 |
van der Zande JJ, Steenwijk MD, Ten Kate M, Wattjes MP, Scheltens P, Lemstra AW. Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology. Neurobiology of Aging. 71: 171-178. PMID 30149288 DOI: 10.1016/J.Neurobiolaging.2018.07.005 |
0.473 |
|
| 2018 |
Wolters EE, Golla SSV, Timmers T, Ossenkoppele R, van der Weijden CWJ, Scheltens P, Schwarte L, Schuit RC, Windhorst AD, Barkhof F, Yaqub M, Lammertsma AA, Boellaard R, van Berckel BNM. A novel partial volume correction method for accurate quantification of [F] flortaucipir in the hippocampus. Ejnmmi Research. 8: 79. PMID 30112620 DOI: 10.1186/S13550-018-0432-2 |
0.374 |
|
| 2018 |
Scheltens NME, Tijms BM, Heymans MW, Rabinovici GD, Cohn-Sheehy BI, Miller BL, Kramer JH, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Scheltens P, van der Flier WM. Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression. Journal of Alzheimer's Disease : Jad. PMID 30103316 DOI: 10.3233/Jad-171088 |
0.436 |
|
| 2018 |
Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Teunissen CE, Dols A, Bouwman FH, Prins ND, Barkhof F, Lammertsma AA, Van Berckel BNM, Scheltens P, Sikkes SAM, Van der Flier WM. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimer's Research & Therapy. 10: 76. PMID 30081935 DOI: 10.1186/S13195-018-0390-Y |
0.447 |
|
| 2018 |
Konijnenberg E, Carter SF, Ten Kate M, den Braber A, Tomassen J, Amadi C, Wesselman L, Nguyen HT, van de Kreeke JA, Yaqub M, Demuru M, Mulder SD, Hillebrand A, Bouwman FH, Teunissen CE, ... ... Scheltens P, et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimer's Research & Therapy. 10: 75. PMID 30075734 DOI: 10.1186/S13195-018-0406-7 |
0.576 |
|
| 2018 |
Gossink F, Pijnenburg Y, Scheltens P, Pera A, Kleverwal R, Korten N, Stek M, Dröes RM, Dols A. An intervention programme for caregivers of dementia patients with frontal behavioural changes: an explorative study with controlled effect on sense of competence. Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society. PMID 30066463 DOI: 10.1111/Psyg.12351 |
0.323 |
|
| 2018 |
de Wilde A, van Buchem MM, Otten RHJ, Bouwman F, Stephens A, Barkhof F, Scheltens P, van der Flier WM. Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimer's Research & Therapy. 10: 72. PMID 30055660 DOI: 10.1186/S13195-018-0398-3 |
0.494 |
|
| 2018 |
Rhodius-Meester HFM, Tijms BM, Lemstra AW, Prins ND, Pijnenburg YAL, Bouwman F, Scheltens P, van der Flier WM. Survival in memory clinic cohort is short, even in young-onset dementia. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 30045942 DOI: 10.1136/Jnnp-2018-318820 |
0.428 |
|
| 2018 |
Ciliz M, Sartor J, Lindig T, Pilotto A, Schäffer E, Weiss M, Scheltens P, Becker S, Hobert MA, Berg D, Liepelt-Scarfone I, Maetzler W. Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease. Journal of Parkinson's Disease. PMID 30040742 DOI: 10.3233/Jpd-181351 |
0.343 |
|
| 2018 |
Groot C, Tolboom N, Ikonomovic MD, Lammertsma AA, Boon BDC, Barkhof F, Scheltens P, Klunk WE, Rozemuller AJM, Ossenkoppele R, van Berckel BNM. Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. Journal of Alzheimer's Disease : Jad. PMID 30040724 DOI: 10.3233/Jad-180316 |
0.419 |
|
| 2018 |
Ganz AB, Beker N, Hulsman M, Sikkes S, Netherlands Brain Bank, Scheltens P, Smit AB, Rozemuller AJM, Hoozemans JJM, Holstege H. Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. Acta Neuropathologica Communications. 6: 64. PMID 30037350 DOI: 10.1186/S40478-018-0558-5 |
0.445 |
|
| 2018 |
van der Zande JJ, Gouw AA, van Steenoven I, Scheltens P, Stam CJ, Lemstra AW. EEG Characteristics of Dementia With Lewy Bodies, Alzheimer's Disease and Mixed Pathology. Frontiers in Aging Neuroscience. 10: 190. PMID 30018548 DOI: 10.3389/Fnagi.2018.00190 |
0.447 |
|
| 2018 |
Linszen MMJ, Lemstra AW, Dauwan M, Brouwer RM, Scheltens P, Sommer IEC. Understanding hallucinations in probable Alzheimer's disease: Very low prevalence rates in a tertiary memory clinic. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 358-362. PMID 30014034 DOI: 10.1016/J.Dadm.2018.03.005 |
0.444 |
|
| 2018 |
Scheltens NME, van der Weijden K, Adriaanse SM, van Assema D, Oomen PP, Krudop WA, Lammertsma AA, Barkhof F, Koene T, Teunissen CE, Scheltens P, van der Flier WM, Pijnenburg YAL, Yaqub M, Ossenkoppele R, et al. Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. Neuroimage. Clinical. 19: 625-632. PMID 29984170 DOI: 10.1016/J.Nicl.2018.05.024 |
0.537 |
|
| 2018 |
Bos I, Vos S, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni G, Molinuevo JL, Wallin A, Lleó A, Popp J, Martinez-Lage P, Baird A, Dobson R, Legido-Quigley C, Sleegers K, et al. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research & Therapy. 10: 64. PMID 29980228 DOI: 10.1186/S13195-018-0396-5 |
0.522 |
|
| 2018 |
Chakraborty A, Chatterjee M, Twaalfhoven H, Del Campo Milan M, Teunissen CE, Scheltens P, Fontijn RD, van Der Flier WM, de Vries HE. Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Alzheimer's Research & Therapy. 10: 58. PMID 29933741 DOI: 10.1186/S13195-018-0385-8 |
0.37 |
|
| 2018 |
Bos I, Verhey FR, Ramakers IHGB, Jacobs HIL, Soininen H, Freund-Levi Y, Hampel H, Tsolaki M, Wallin ÅK, van Buchem MA, Oleksik A, Verbeek MM, Rikkert MO, van der Flier WM, Scheltens P, et al. Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research & Therapy. 10: 56. PMID 29925412 DOI: 10.1186/S13195-018-0391-X |
0.363 |
|
| 2018 |
Tolonen A, Rhodius-Meester HFM, Bruun M, Koikkalainen J, Barkhof F, Lemstra AW, Koene T, Scheltens P, Teunissen CE, Tong T, Guerrero R, Schuh A, Ledig C, Baroni M, Rueckert D, et al. Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Frontiers in Aging Neuroscience. 10: 111. PMID 29922145 DOI: 10.3389/Fnagi.2018.00111 |
0.509 |
|
| 2018 |
de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, van Buchem MM, Zwan M, Ossenkoppele R, Yaqub M, Kunneman M, Smets EMA, Barkhof F, Lammertsma AA, Stephens A, ... ... Scheltens P, et al. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. Jama Neurology. PMID 29889941 DOI: 10.1001/Jamaneurol.2018.1346 |
0.432 |
|
| 2018 |
Boon BDC, Hoozemans JJM, Lopuhaä B, Eigenhuis KN, Scheltens P, Kamphorst W, Rozemuller AJM, Bouwman FH. Neuroinflammation is increased in the parietal cortex of atypical Alzheimer's disease. Journal of Neuroinflammation. 15: 170. PMID 29843759 DOI: 10.1186/S12974-018-1180-Y |
0.454 |
|
| 2018 |
Jutten RJ, Harrison J, Lee Meeuw Kjoe PR, Opmeer EM, Schoonenboom NSM, de Jong FJ, Ritchie CW, Scheltens P, Sikkes SAM. A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibility. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 153-160. PMID 29780863 DOI: 10.1016/J.Dadm.2017.12.002 |
0.434 |
|
| 2018 |
Leeuwis AE, Prins ND, Hooghiemstra AM, Benedictus MR, Scheltens P, Barkhof F, van der Flier WM. Microbleeds are associated with depressive symptoms in Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 112-120. PMID 29780860 DOI: 10.1016/J.Dadm.2017.11.006 |
0.395 |
|
| 2018 |
Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS, Villeneuve S. Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 3: 463-472. PMID 29735156 DOI: 10.1016/J.Bpsc.2017.11.012 |
0.458 |
|
| 2018 |
Claus JJ, Coenen M, Staekenborg SS, Schuur J, Tielkes CEM, Koster P, Scheltens P. Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population. Journal of Alzheimer's Disease : Jad. PMID 29710708 DOI: 10.3233/Jad-171111 |
0.35 |
|
| 2018 |
Scheltens P, Prins N, Lammertsma A, Yaqub M, Gouw A, Wink AM, Chu HM, van Berckel BNM, Alam J. An exploratory clinical study of p38 kinase inhibition in Alzheimer's disease. Annals of Clinical and Translational Neurology. 5: 464-473. PMID 29687023 DOI: 10.1002/Acn3.549 |
0.423 |
|
| 2018 |
Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, ... ... Scheltens P, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 14: 535-562. PMID 29653606 DOI: 10.1016/J.Jalz.2018.02.018 |
0.482 |
|
| 2018 |
Dauwan M, Linszen MMJ, Lemstra AW, Scheltens P, Stam CJ, Sommer IE. EEG-based neurophysiological indicators of hallucinations in Alzheimer's disease: Comparison with dementia with Lewy bodies. Neurobiology of Aging. 67: 75-83. PMID 29653315 DOI: 10.1016/J.Neurobiolaging.2018.03.013 |
0.331 |
|
| 2018 |
Bouts MJRJ, Möller C, Hafkemeijer A, van Swieten JC, Dopper E, van der Flier WM, Vrenken H, Wink AM, Pijnenburg YAL, Scheltens P, Barkhof F, Schouten TM, de Vos F, Feis RA, van der Grond J, et al. Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. Journal of Alzheimer's Disease : Jad. PMID 29614652 DOI: 10.3233/Jad-170893 |
0.543 |
|
| 2018 |
Teunissen CE, Chiu MJ, Yang CC, Yang SY, Scheltens P, Zetterberg H, Blennow K. Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 29614646 DOI: 10.3233/Jad-170784 |
0.393 |
|
| 2018 |
Vermunt L, Veal CD, Meulen LT, Chrysostomou C, van der Flier W, Frisoni GB, Guessous I, Kivipelto M, Marizzoni M, Martinez-Lage P, Molinuevo JL, Porteus D, Ritchie K, Scheltens P, Ousset PJ, et al. European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29604264 DOI: 10.1016/J.Jalz.2018.02.010 |
0.433 |
|
| 2018 |
Verfaillie SCJ, Slot RER, Dicks E, Prins ND, Overbeek JM, Teunissen CE, Scheltens P, Barkhof F, van der Flier WM, Tijms BM. A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. Human Brain Mapping. PMID 29602212 DOI: 10.1002/Hbm.24065 |
0.504 |
|
| 2018 |
Mattsson N, Groot C, Jansen WJ, Landau S, Villemagne V, Engelborghs S, Mintun M, Lleo A, Molinuevo JL, Jagust W, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, ... ... Scheltens P, et al. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29601787 DOI: 10.1016/J.Jalz.2018.02.009 |
0.41 |
|
| 2018 |
Ten Kate M, Visser PJ, Bakardjian H, Barkhof F, Sikkes SAM, van der Flier WM, Scheltens P, Hampel H, Habert MO, Dubois B, Tijms BM. Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Frontiers in Aging Neuroscience. 10: 67. PMID 29599717 DOI: 10.3389/Fnagi.2018.00067 |
0.533 |
|
| 2018 |
van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. Journal of Alzheimer's Disease : Jad. 62: 1091-1111. PMID 29562540 DOI: 10.3233/Jad-170850 |
0.364 |
|
| 2018 |
Leijenaar JF, Groeneveld GJ, van der Flier WM, Scheltens P, Klaassen ES, Weinstein HC, Biessels GJ, Barkhof F, Prins ND. Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. Jmir Research Protocols. 7: e80. PMID 29559423 DOI: 10.2196/Resprot.9192 |
0.47 |
|
| 2018 |
Willemse EAJ, De Vos A, Herries EM, Andreasson U, Engelborghs S, van der Flier WM, Scheltens P, Crimmins D, Ladenson JH, Vanmechelen E, Zetterberg H, Fagan AM, Blennow K, Bjerke M, Teunissen CE. Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. Clinical Chemistry. PMID 29523639 DOI: 10.1373/Clinchem.2017.283028 |
0.464 |
|
| 2018 |
Ten Kate M, Sudre CH, den Braber A, Konijnenberg E, Nivard MG, Cardoso MJ, Scheltens P, Ourselin S, Boomsma DI, Barkhof F, Visser PJ. White matter hyperintensities and vascular risk factors in monozygotic twins. Neurobiology of Aging. 66: 40-48. PMID 29505954 DOI: 10.1016/J.Neurobiolaging.2018.02.002 |
0.386 |
|
| 2018 |
Gossink F, Schouws S, Krudop W, Scheltens P, Stek M, Pijnenburg Y, Dols A. Social Cognition Differentiates Behavioral Variant Frontotemporal Dementia From Other Neurodegenerative Diseases and Psychiatric Disorders. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 29501411 DOI: 10.1016/J.Jagp.2017.12.008 |
0.378 |
|
| 2018 |
Rhodius-Meester HFM, Liedes H, Koene T, Lemstra AW, Teunissen CE, Barkhof F, Scheltens P, van Gils M, Lötjönen J, van der Flier WM. Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. Alzheimer's Research & Therapy. 10: 23. PMID 29458426 DOI: 10.1186/S13195-018-0348-0 |
0.536 |
|
| 2018 |
van der Flier WM, Skoog I, Schneider JA, Pantoni L, Mok V, Chen CLH, Scheltens P. Vascular cognitive impairment. Nature Reviews. Disease Primers. 4: 18003. PMID 29446769 DOI: 10.1038/nrdp.2018.3 |
0.335 |
|
| 2018 |
Duits FH, Brinkmalm G, Teunissen CE, Brinkmalm A, Scheltens P, Van der Flier WM, Zetterberg H, Blennow K. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. Alzheimer's Research & Therapy. 10: 5. PMID 29370833 DOI: 10.1186/S13195-017-0335-X |
0.457 |
|
| 2018 |
van der Lee SJ, Teunissen CE, Pool R, Shipley MJ, Teumer A, Chouraki V, Melo van Lent D, Tynkkynen J, Fischer K, Hernesniemi J, Metspalu A, Singh-Manoux A, Verhoeven A, Willemsen G, de Leeuw FA, ... ... Scheltens P, et al. Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29316447 DOI: 10.1016/J.Jalz.2017.11.012 |
0.41 |
|
| 2018 |
den Haan J, Janssen SF, van de Kreeke JA, Scheltens P, Verbraak FD, Bouwman FH. Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer's disease and controls. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 49-55. PMID 29201990 DOI: 10.1016/J.Dadm.2017.10.005 |
0.409 |
|
| 2018 |
Visser D, Ossenkoppele R, Verfaillie SCJ, Timmers T, Wolters EE, Golla SSV, Boellaard R, Windhorst AD, Scheltens P, Flier WMVd, Berckel BNMv. P4-306: The Association Between [18F]Av1451 Pet And Cognitive Performance Across The Alzheimer'S Disease Spectrum Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.07.129 |
0.361 |
|
| 2018 |
Hanes J, Kontsekova E, Kovac A, Katina S, Teunissen CE, Vyhnalek M, Hort J, Zilka N, Scheltens P. Dt‐02‐02: Novel Ultrasensitive Immunoassay Detecting P‐Tau Thr217 Completely Distinguishes Alzheimer'S Disease From Frontotemporal Lobar Degeneration Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.07.011 |
0.357 |
|
| 2018 |
Leeuw FAd, Flier WMVd, Scheltens P, Mendes VM, Wijk Nv, Heuvel EGHMvd, Mohajeri HM, Teunissen CE, Kester MI. P2-284: Nutritional Markers Associated With Clinical Progression In Patients With Mild Cognitive Impairment And Subjective Cognitive Decline: The Nudad Study Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.973 |
0.365 |
|
| 2018 |
Haan Jd, Morrema THJ, Brink JBt, Verbraak F, Boer Jd, Scheltens P, Rozemuller AM, Bergen AAB, Bouwman FH, Hoozemans JJM. P2-251: Neuropathological Hallmarks Of Alzheimer'S Disease In Postmortem Ad Retinas Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.940 |
0.394 |
|
| 2018 |
Gupta V, Chatterjee M, Tijms BM, Leeuw FAd, Scheltens P, Flier WMVd, Teunissen CE. P2-248: Contactin-2 As A Potential Biomarker For Mild Cognitive Impairment Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.935 |
0.342 |
|
| 2018 |
Tesi N, Lee SJVd, Hulsman M, Jansen IE, Stringa N, Schoor Nv, Meijers-Heijboer H, Huisman M, Scheltens P, Reinders MJ, Flier WMVd, Holstege H. P2-134: The Added Value Of Extreme Phenotypes In Alzheimer'S Disease Case-Control Studies Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.820 |
0.381 |
|
| 2018 |
Sikkes SAM, Verrijp M, Epelbaum S, Habert M, Hampel H, Vannini P, Marshall GA, Porsius J, Bakardjian H, Scheltens P, Dubois B. P1-627: Amyloid Burden Impacts Everyday Functioning Independent Of Cognition And Awareness In Subjective Cognitive Decline: Findings From The Insight Pre-Ad Cohort Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.640 |
0.398 |
|
| 2018 |
Tomassen J, Braber Ad, Konijnenberg E, Kate Mt, Mulder SD, Teunissen CE, Boomsma DI, Scheltens P, Visser PJ. P1-525: Amyloid Aggregation Is Associated With Decline On Digit Span Backward In Cognitively Normal Elderly Monozygotic Twins Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.536 |
0.336 |
|
| 2018 |
Meester HFR, Tijms BM, Lemstra E, Prins ND, Pijnenburg YAL, Bouwman FH, Scheltens P, Flier WMVd. P1-357: Median Survival In Memory Clinic Cohort Is Short, Even In Young-Onset Dementia Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.365 |
0.318 |
|
| 2018 |
Verrijp M, Dubbelman MA, Jutten RJ, Beker N, Wesselman LMP, Sikkes SAM, Scheltens P. P1-333: Detecting Clinically Relevant Changes In Dementia Using Instrumental Activities Of Daily Living: A Longitudinal Validation Study With 3, 6, 9 And 12 Months Follow-Up Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.340 |
0.318 |
|
| 2018 |
Leeuwis AE, Weaver NA, Biesbroek JM, Kuijf HJ, Hooghiemstra AM, Prins ND, Scheltens P, Barkhof F, Flier WMVd, Biessels GJ. O1-14-04: Impact Of White Matter Hyperintensity Location On Depressive Symptoms In Memory Clinic Patients: A Lesion-Symptom Mapping Study Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.3050 |
0.375 |
|
| 2018 |
Leeuw FAd, Tijms BM, Peeters CFW, Kester MI, Scheltens P, Duijn CMv, Barkhof F, Teunissen CE, Flier WMVd. P1-297: Metabolic Blood-Based Biomarkers Relate To Brain Atrophy And White Matter Hyperintensities In Alzheimer'S Disease Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.303 |
0.488 |
|
| 2018 |
Kate Mt, Dicks E, Flier WMVd, Teunissen CE, Scheltens P, Barkhof F, Visser PJ, Tijms BM, Initiative ADN, Cohort AD. O5-01-03: Atrophy Subtypes In Alzheimer'S Disease Identified Through Non-Negative Matrix Factorization Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2997 |
0.452 |
|
| 2018 |
Loenhoud ACv, Flier WMVd, Wink AM, Dicks E, Groot C, Twisk JW, Barkhof F, Scheltens P, Ossenkoppele R. The Use Of Residual Methods To Capture Cognitive Reserve And Study Clinical Progression In Alzheimer’S Disease Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2987 |
0.481 |
|
| 2018 |
Verberk IMW, Slot RER, Verfaillie SCJ, Heijst H, Prins ND, Scheltens P, Teunissen CE, Flier WMVd. F4-08-01: Plasma Amyloid As A Pre-Screening Tool For Amyloid Positivity In Subjective Cognitive Decline Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2892 |
0.327 |
|
| 2018 |
Maurik ISv, Vos SJB, Bos I, Bouwman FH, Tijms BM, Teunissen CE, Barkhof F, Scheltens P, Palmqvist S, Hansson O, Visser PJ, Berkhof J, Flier WMVd. O2-15-04: Robust Individualized Prediction Models Which Are Applicable Across Different Cohorts Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2727 |
0.339 |
|
| 2018 |
Pijnenburg YAL, Vijverberg E, Krudop WA, Gossink FT, Prins ND, Schouws S, Teunissen CE, Barkhof F, Berckel BNMv, Stek ML, Scheltens P, Dols A. O2-14-04: Identifying Behavioral Variant Frontotemporal Dementia Among Patients With A Late-Onset Frontal Lobe Syndrome: Summary Results Of The Lof Study Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2721 |
0.436 |
|
| 2018 |
Collij L, Heeman F, Konijnenberg E, Braber Ad, Yaqub MM, Visser PJ, Wink AM, Scheltens P, Boellaard R, Berckel BNMv, Schmidt ME, Barkhof F, Alves IL. Extension And Validation Of An Amyloid Staging Model: Associations With Clinical Measures Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2692 |
0.405 |
|
| 2018 |
Verfaillie SCJ, Timmers T, Slot RER, Weijden CWJvd, Wesselman LMP, Prins ND, Sikkes SAM, Lammertsma AA, Scheltens P, Ossenkoppele R, Berckel BNMv, Flier WMVd. O2-06-03: AMYLOID-β LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2671 |
0.304 |
|
| 2018 |
Reimand J, Wilde Ad, Berckel BNMv, Teunissen CE, Scheltens P, Ossenkoppele R, Bouwman FH. O2-04-02: Longitudinal Cognitive Trajectories Of Patients With Discordant Csf And Pet Amyloid Biomarkers Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2658 |
0.353 |
|
| 2018 |
Mofrad RB, Tijms BM, Scheltens P, Flier WMVd, Sikkes SAM, Teunissen CE. P1-259: Sex Differences In Cerebrospinal Fluid Biomarker Concentrations Across Clinical Stages Of Alzheimer'S Disease Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.265 |
0.344 |
|
| 2018 |
Hong S, Dobricic V, Smith RG, Küçükali F, Kilpert F, Bos I, Vos SJB, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni GB, Blin O, Richardson J, Bordet R, Tsolaki M, et al. F1-02-04: Genomics And Epigenomics Analyses In The Emif-Ad Multimodal Biomarker Discovery Study Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2310 |
0.427 |
|
| 2018 |
Bos I, Vos SJB, Verhey FRJ, Scheltens P, Engelborghs S, Frisoni GB, Blin O, Richardson J, Bordet R, Tsolaki M, Popp J, Martinez-Lage P, Lleó A, Johannsen P, Freund-Levi Y, et al. F1-02-01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT-LIGHT AND YKL-40 TO Aβ, APOE ε4 AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2307 |
0.516 |
|
| 2018 |
Timmers T, Ossenkoppele R, Wolters EE, Visser D, Barkhof F, Golla SSV, Boellaard R, Windhorst AD, Scheltens P, Flier WMVd, Berckel BNMv. Ic-P-222: [18F]Av1451 Pet In Relation To Atrophy Across The Alzheimer'S Disease Spectrum Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2289 |
0.448 |
|
| 2018 |
Loenhoud ACv, Flier WMVd, Wink AM, Dicks E, Groot C, Twisk JW, Barkhof F, Scheltens P, Ossenkoppele R. Disease-Stage Specific Relationship Between Cognitive Reserve And Clinical Progression In Alzheimer’S Disease Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2259 |
0.486 |
|
| 2018 |
Singleton EH, Pijnenburg YAL, Sudre CH, Kochova E, Groot C, Papma JM, Ourselin S, Swieten JCv, Barkhof F, Cardoso MJ, Scheltens P, Rabinovici GD, Ossenkoppele R. Ic-P-110: Patterns Of Glucose Hypometabolism, Subcortical Atrophy And White Matter Hyperintensities In The Behavioral Variant Of Alzheimer'S Disease Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2176 |
0.458 |
|
| 2018 |
Groot C, Yeo T, Vogel JW, Zhang EX, Suna N, Crane PK, Rabinovici GD, Mormino BC, Pijnenburg YAL, Barkhof F, Scheltens P, Flier WMVd, Ossenkoppele R. Ic-P-093: Latent Atrophy Factors In Posterior Cortical Atrophy Relate To Specific Cognitive Impairments Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2157 |
0.457 |
|
| 2018 |
Braber Ad, Stickney K, Ent Dv', Kate Mt, Konijnenberg E, Tomassen J, Barkhof F, Berckel BNMv, Boomsma DI, Geus Ed, Scheltens P, Visser PJ. Ic-P-066: White Matter Microstructure And Amyloid Aggregation In Cognitively Healthy, Elderly Identical Twins Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2131 |
0.51 |
|
| 2018 |
Collij L, Konijnenberg E, Reimand J, Kate Mt, Braber Ad, Alves IL, Zwan MD, Yaqub MM, Assema Dv, Wink AM, Lammertsma AA, Scheltens P, Visser PJ, Barkhof F, Berckel BNMv. Assessment Of Early Amyloid Pathology Using [18F]Flutemetamol Positron Emission Tomography: Comparing Visual Read, Semi-Quantitative And Quantitative Methods Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2069 |
0.394 |
|
| 2018 |
Tijms BM, Dicks E, Scheltens P, Barkhof F, Flier WMVd. Ic-06-05: Loss Of Grey Matter Connectivity In The Precuneus Is Associated With Faster Atrophy Rates In Preclinical Alzheimer'S Disease Alzheimers & Dementia. 14: 13. DOI: 10.1016/J.Jalz.2018.06.2058 |
0.479 |
|
| 2018 |
Wesselman LMP, Doorduijn A, Verfaillie SCJ, Slot RER, Kester MI, Prins ND, Schueren Mdvd, Scheltens P, Flier WMVd, Sikkes SAM. P3-617: Nutritional Intake In Subjective Cognitive Decline: Room For Improvement? Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.1984 |
0.312 |
|
| 2018 |
Vermunt L, Visser PJ, Scheltens P, Tijms BM, Adni. P3-568: Prognosis Of Individuals With Mild Cognitive Impairment Reverting To Normal Cognition Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.1934 |
0.332 |
|
| 2018 |
Verfaillie SCJ, Golla SSV, Weijden CWJvd, Timmers T, Schober P, Schuit RC, Windhorst AD, Scheltens P, Flier WMVd, Lammertsma AA, Berckel BNMv, Boellaard R. Parametric Imaging Of [18F]Florbetapir: A Test-Retest Study In Healthy Subjects And Patients With Alzheimer’S Disease Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.1801 |
0.304 |
|
| 2018 |
Dicks E, He Y, Beg F, Biessels GJ, Carmeli C, Chen G, Çiftçi K, Dai Z, Dellen EV, Dyrba M, Friedman EJ, Haan Wd, Jalili M, Jeong J, Jeong Y, ... ... Scheltens P, et al. Ic-P-032: Influence Of Network Construction Methods On Path Length Values In Alzheimer'S Disease: A Multi-Study Analysis Of Mri Connectivity Studies Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.1703 |
0.456 |
|
| 2018 |
Jutten RJ, Dicks E, Vermaat LEW, Barkhof F, Scheltens P, Tijms BM, Sikkes SAM. P3-277: Impairment In Complex Activities Of Daily Living Is Related To Neurodegeneration In Alzheimer'S Disease Specific Regions Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.1637 |
0.501 |
|
| 2018 |
Briels CT, Stam CJ, Scheltens P, Gouw AA. P3-272: A Comparison Of Eeg Connectivity Outcome Measures For Alzheimer'S Disease In A Double-Blinded Randomized Clinical Trial Of Pq912 Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.1632 |
0.324 |
|
| 2018 |
Kim M, Snowden SG, Ahmad T, Westwood S, Baird AL, Proitsi P, Nevado-Holgado AJ, Hye A, Ashton NJ, Bos I, Vos SJB, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni GB, et al. P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER\textquotesingleS DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.1592 |
0.515 |
|
| 2018 |
Legdeur N, Badissi M, Collij L, Heeman F, Berckel BNMv, Barkhof F, Scheltens P, Muller M, Maier AB, Visser PJ. P3-216: Is The Relation Between Blood Pressure And Cognition Dependent On Amyloid Pathology Or Physical Performance? Results Of The Emif-Ad 90+ Study Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.1575 |
0.5 |
|
| 2018 |
Boon BDC, Hoozemans JJM, Scheltens P, Rozemuller AM, Bouwman FH. P2-470: Different Co-Localization Of Neuroinflammatory Markers In Plaques Of Atypical Compared To Typical Alzheimer'S Disease Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.1163 |
0.365 |
|
| 2018 |
Rhodius-Meester HFM, Bruun M, Baroni M, Gjerum L, Remes AM, Urhemaa T, Tolonen A, Rueckert D, Gils Mv, Lemstra E, Barkhof F, Frederiksen KS, Waldemar G, Scheltens P, Soininen H, et al. Different combinations of diagnostic tests discriminate specific subtypes of dementia Alzheimers & Dementia. 10: 820-821. DOI: 10.1016/J.Jalz.2018.06.1039 |
0.435 |
|
| 2018 |
Leijenaar JF, Klaassen ES, Leeuwis AE, Groeneveld GJ, Flier WMVd, Scheltens P, Weinstein HC, Biessels GJ, Barkhof F, Prins ND. Methylphenidate Improves Executive Functioning In Patients With Vascular Cognitive Impairment: First Results Of The Stream-Vci Study Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.017 |
0.464 |
|
| 2017 |
Bos I, Verhey FR, Ramakers IHGB, Jacobs HIL, Soininen H, Freund-Levi Y, Hampel H, Tsolaki M, Wallin ÅK, van Buchem MA, Oleksik A, Verbeek MM, Olde Rikkert M, van der Flier WM, Scheltens P, et al. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research & Therapy. 9: 101. PMID 29284531 DOI: 10.1186/S13195-017-0328-9 |
0.446 |
|
| 2017 |
Groot C, van Loenhoud AC, Barkhof F, van Berckel BNM, Koene T, Teunissen CC, Scheltens P, van der Flier WM, Ossenkoppele R. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology. PMID 29237798 DOI: 10.1212/Wnl.0000000000004802 |
0.522 |
|
| 2017 |
Leijenaar JF, van Maurik IS, Kuijer JPA, van der Flier WM, Scheltens P, Barkhof F, Prins ND. Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. Alzheimer's & Dementia (Amsterdam, Netherlands). 9: 76-83. PMID 29234724 DOI: 10.1016/J.Dadm.2017.10.001 |
0.527 |
|
| 2017 |
Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimer's Research & Therapy. 9: 95. PMID 29221491 DOI: 10.1186/S13195-017-0318-Y |
0.488 |
|
| 2017 |
Tijms BM, Willemse EAJ, Zwan MD, Mulder SD, Visser PJ, van Berckel BNM, van der Flier WM, Scheltens P, Teunissen CE. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results. Clinical Chemistry. PMID 29208658 DOI: 10.1373/Clinchem.2017.281055 |
0.393 |
|
| 2017 |
Piersma D, Fuermaier ABM, De Waard D, Davidse RJ, De Groot J, Doumen MJA, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, De Deyn PP, Brouwer WH, et al. Assessing Fitness to Drive in Patients With Different Types of Dementia. Alzheimer Disease and Associated Disorders. PMID 29189301 DOI: 10.1097/Wad.0000000000000221 |
0.432 |
|
| 2017 |
Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A, Engelborghs S, Na DL, ... ... Scheltens P, et al. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. Jama Psychiatry. PMID 29188296 DOI: 10.1001/Jamapsychiatry.2017.3391 |
0.445 |
|
| 2017 |
Bertens D, Tijms BM, Vermunt L, Prins ND, Scheltens P, Visser PJ. The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design. Alzheimer's & Dementia (New York, N. Y.). 3: 513-523. PMID 29124109 DOI: 10.1016/J.Trci.2017.08.005 |
0.446 |
|
| 2017 |
Dicks E, Tijms BM, Ten Kate M, Gouw AA, Benedictus MR, Teunissen CE, Barkhof F, Scheltens P, van der Flier WM. Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiology of Aging. 61: 198-206. PMID 29111486 DOI: 10.1016/J.Neurobiolaging.2017.09.029 |
0.499 |
|
| 2017 |
Vijverberg EGB, Gossink F, Krudop W, Sikkes S, Kerssens C, Prins N, Stek M, Scheltens P, Pijnenburg Y, Dols A. The Diagnostic Challenge of the Late-Onset Frontal Lobe Syndrome: Clinical Predictors for Primary Psychiatric Disorders Versus Behavioral Variant Frontotemporal Dementia. The Journal of Clinical Psychiatry. PMID 29099546 DOI: 10.4088/Jcp.16M11078 |
0.332 |
|
| 2017 |
Jutten RJ, Harrison J, de Jong FJ, Aleman A, Ritchie CW, Scheltens P, Sikkes SAM. A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study. Alzheimer's & Dementia (New York, N. Y.). 3: 130-138. PMID 29067324 DOI: 10.1016/J.Trci.2017.01.004 |
0.454 |
|
| 2017 |
Vandenberghe R, Riviere ME, Caputo A, Sovago J, Maguire RP, Farlow M, Marotta G, Sanchez-Valle R, Scheltens P, Ryan JM, Graf A. Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study. Alzheimer's & Dementia (New York, N. Y.). 3: 10-22. PMID 29067316 DOI: 10.1016/J.Trci.2016.12.003 |
0.4 |
|
| 2017 |
Sartor J, Bettecken K, Bernhard FP, Hofmann M, Gladow T, Lindig T, Ciliz M, Ten Kate M, Geritz J, Heinzel S, Benedictus M, Scheltens P, Hobert MA, Maetzler W. Corrigendum: White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson's Disease. Frontiers in Aging Neuroscience. 9: 342. PMID 29056907 DOI: 10.3389/Fnagi.2017.00342 |
0.328 |
|
| 2017 |
van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. Jama Neurology. PMID 29049480 DOI: 10.1001/Jamaneurol.2017.2712 |
0.564 |
|
| 2017 |
Skillbäck T, Mattsson N, Hansson K, Mirgorodskaya E, Dahlén R, van der Flier W, Scheltens P, Duits F, Hansson O, Teunissen C, Blennow K, Zetterberg H, Gobom J. A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. Scientific Reports. 7: 13333. PMID 29042634 DOI: 10.1038/S41598-017-13831-0 |
0.421 |
|
| 2017 |
Tijms BM, Ten Kate M, Gouw AA, Borta A, Verfaillie S, Teunissen CE, Scheltens P, Barkhof F, van der Flier WM. Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. Neurobiology of Aging. 61: 75-81. PMID 29040871 DOI: 10.1016/J.Neurobiolaging.2017.09.011 |
0.535 |
|
| 2017 |
Reijs BLR, Vos SJB, Soininen H, Lötjonen J, Koikkalainen J, Pikkarainen M, Hall A, Vanninen R, Liu Y, Herukka SK, Freund-Levi Y, Frisoni GB, Frölich L, Nobili F, Rikkert MO, ... ... Scheltens P, et al. Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. Journal of Alzheimer's Disease : Jad. PMID 29036813 DOI: 10.3233/Jad-170039 |
0.44 |
|
| 2017 |
Verfaillie SCJ, Slot RE, Tijms BM, Bouwman F, Benedictus MR, Overbeek JM, Koene T, Vrenken H, Scheltens P, Barkhof F, van der Flier WM. Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. Neurobiology of Aging. PMID 29029762 DOI: 10.1016/J.Neurobiolaging.2017.09.009 |
0.508 |
|
| 2017 |
Krudop WA, Dols A, Kerssens CJ, Eikelenboom P, Prins ND, Möller C, Schouws S, Rhebergen D, van Exel E, van der Flier WM, Sikkes S, Scheltens P, Stek ML, Pijnenburg YAL. The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria. Journal of Alzheimer's Disease : Jad. 60: 959-975. PMID 28984605 DOI: 10.3233/Jad-170608 |
0.303 |
|
| 2017 |
de Leeuw FA, Peeters CFW, Kester MI, Harms AC, Struys EA, Hankemeier T, van Vlijmen HWT, van der Lee SJ, van Duijn CM, Scheltens P, Demirkan A, van de Wiel MA, van der Flier WM, Teunissen CE. Blood-based metabolic signatures in Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 8: 196-207. PMID 28951883 DOI: 10.1016/J.Dadm.2017.07.006 |
0.315 |
|
| 2017 |
Ten Kate M, Barkhof F, Visser PJ, Teunissen CE, Scheltens P, van der Flier WM, Tijms BM. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimer's Research & Therapy. 9: 73. PMID 28899429 DOI: 10.1186/S13195-017-0299-X |
0.573 |
|
| 2017 |
Miller AM, Balasa M, Blennow K, Gardiner M, Rutkowska A, Scheltens P, Teunissen CE, Visser PJ, Winblad B, Waldemar G, Lawlor B. Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. Journal of Alzheimer's Disease : Jad. PMID 28826189 DOI: 10.3233/Jad-170502 |
0.338 |
|
| 2017 |
Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B. On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimer's Research & Therapy. 9: 60. PMID 28793924 DOI: 10.1186/S13195-017-0283-5 |
0.436 |
|
| 2017 |
Morbelli S, Bauckneht M, Scheltens P. Imaging biomarkers in Alzheimer's Disease: added value in the clinical setting. The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (Aimn) [and] the International Association of Radiopharmacology (Iar), [and] Section of the Society of.... PMID 28750495 DOI: 10.23736/S1824-4785.17.03011-4 |
0.469 |
|
| 2017 |
Vijverberg EGB, Schouws S, Meesters PD, Verwijk E, Comijs H, Koene T, Schreuder C, Beekman A, Scheltens P, Stek M, Pijnenburg Y, Dols A. Cognitive Deficits in Patients With Neuropsychiatric Symptoms: A Comparative Study Between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders. The Journal of Clinical Psychiatry. PMID 28749089 DOI: 10.4088/Jcp.16M11019 |
0.307 |
|
| 2017 |
Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR, Nobili F, Nordberg A, ... ... Scheltens P, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. The Lancet. Neurology. 16: 661-676. PMID 28721928 DOI: 10.1016/S1474-4422(17)30159-X |
0.484 |
|
| 2017 |
Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, Mulder SD, Scheltens P, Xiong C, Fagan AM. Upward drift in cerebrospinal fluid amyloid-β 42 assay values for more than 10 years. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28710906 DOI: 10.1016/J.Jalz.2017.06.2264 |
0.37 |
|
| 2017 |
van Wijk N, Slot RER, Duits FH, Strik M, Biesheuvel E, Sijben JWC, Blankenstein MA, Bierau J, van der Flier WM, Scheltens P, Teunissen CE. Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. Alzheimer's & Dementia (Amsterdam, Netherlands). 8: 139-146. PMID 28653034 DOI: 10.1016/J.Dadm.2017.04.005 |
0.454 |
|
| 2017 |
Gouw AA, Alsema AM, Tijms BM, Borta A, Scheltens P, Stam CJ, van der Flier WM. EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. Neurobiology of Aging. 57: 133-142. PMID 28646686 DOI: 10.1016/J.Neurobiolaging.2017.05.017 |
0.408 |
|
| 2017 |
van Loenhoud AC, Wink AM, Groot C, Verfaillie SCJ, Twisk J, Barkhof F, van Berckel B, Scheltens P, van der Flier WM, Ossenkoppele R. A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. Human Brain Mapping. PMID 28631336 DOI: 10.1002/Hbm.23695 |
0.534 |
|
| 2017 |
Babapour Mofrad R, Bouwman FH, Slot RER, Timmers T, van der Flier WM, Scheltens P, Teunissen CE. Lumbar puncture in patients with neurologic conditions. Alzheimer's & Dementia (Amsterdam, Netherlands). 8: 108-110. PMID 28603767 DOI: 10.1016/J.Dadm.2017.04.008 |
0.369 |
|
| 2017 |
Bridel C, Hoffmann T, Meyer A, Durieux S, Koel-Simmelink MA, Orth M, Scheltens P, Lues I, Teunissen CE. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients. Alzheimer's Research & Therapy. 9: 38. PMID 28587659 DOI: 10.1186/S13195-017-0266-6 |
0.408 |
|
| 2017 |
van Harten AC, Jongbloed W, Teunissen CE, Scheltens P, Veerhuis R, van der Flier WM. CSF ApoE predicts clinical progression in nondemented APOEε4 carriers. Neurobiology of Aging. PMID 28571653 DOI: 10.1016/J.Neurobiolaging.2017.04.002 |
0.419 |
|
| 2017 |
Holstege H, van der Lee SJ, Hulsman M, Wong TH, van Rooij JG, Weiss M, Louwersheimer E, Wolters FJ, Amin N, Uitterlinden AG, Hofman A, Ikram MA, van Swieten JC, Meijers-Heijboer H, van der Flier WM, ... ... Scheltens P, et al. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. European Journal of Human Genetics : Ejhg. PMID 28537274 DOI: 10.1038/Ejhg.2017.87 |
0.357 |
|
| 2017 |
Rhodius-Meester HFM, Benedictus MR, Wattjes MP, Barkhof F, Scheltens P, Muller M, van der Flier WM. MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Frontiers in Aging Neuroscience. 9: 117. PMID 28536518 DOI: 10.3389/Fnagi.2017.00117 |
0.509 |
|
| 2017 |
López ME, Engels MMA, van Straaten ECW, Bajo R, Delgado ML, Scheltens P, Hillebrand A, Stam CJ, Maestú F. MEG Beamformer-Based Reconstructions of Functional Networks in Mild Cognitive Impairment. Frontiers in Aging Neuroscience. 9: 107. PMID 28487647 DOI: 10.3389/Fnagi.2017.00107 |
0.363 |
|
| 2017 |
Bos I, Vos SJ, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Engelborghs S, Niemantsverdriet E, De Roeck EE, Tsolaki M, Freund-Levi Y, Johannsen P, Vandenberghe R, ... ... Scheltens P, et al. The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging. 56: 33-40. PMID 28482212 DOI: 10.1016/J.Neurobiolaging.2017.03.034 |
0.465 |
|
| 2017 |
Harper L, Bouwman F, Burton EJ, Barkhof F, Scheltens P, O'Brien JT, Fox NC, Ridgway GR, Schott JM. Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 28473626 DOI: 10.1136/Jnnp-2016-314978 |
0.496 |
|
| 2017 |
Jutten RJ, Peeters CFW, Leijdesdorff SMJ, Visser PJ, Maier AB, Terwee CB, Scheltens P, Sikkes SAM. Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimer's & Dementia (Amsterdam, Netherlands). 8: 26-35. PMID 28462387 DOI: 10.1016/J.Dadm.2017.03.002 |
0.318 |
|
| 2017 |
Gossink FT, Vijverberg EG, Krudop W, Scheltens P, Stek ML, Pijnenburg YA, Dols A. Psychosis in behavioral variant frontotemporal dementia. Neuropsychiatric Disease and Treatment. 13: 1099-1106. PMID 28458550 DOI: 10.2147/Ndt.S127863 |
0.401 |
|
| 2017 |
Boomsma JMF, Exalto LG, Barkhof F, van den Berg E, de Bresser J, Heinen R, Koek HL, Prins ND, Scheltens P, Weinstein HC, van der Flier WM, Biessels GJ. Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the "Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment" (TRACE-VCI) Study. Jmir Research Protocols. 6: e60. PMID 28428166 DOI: 10.2196/Resprot.6864 |
0.482 |
|
| 2017 |
Scheltens NME, Tijms BM, Koene T, Barkhof F, Teunissen CE, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Cohn-Sheehy BI, Rabinovici GD, Miller BL, Kramer JH, Scheltens P, van der Flier WM, et al. Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28427934 DOI: 10.1016/J.Jalz.2017.03.002 |
0.567 |
|
| 2017 |
Golla SS, Timmers T, Ossenkoppele R, Groot C, Verfaillie S, Scheltens P, van der Flier WM, Schwarte L, Mintun MA, Devous M, Schuit RC, Windhorst AD, Lammertsma AA, Boellaard R, van Berckel BN, et al. Quantification of Tau Load Using [(18)F]AV1451 PET. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 28374171 DOI: 10.1007/S11307-017-1080-Z |
0.332 |
|
| 2017 |
Mo Y, Stromswold J, Wilson K, Holder D, Sur C, Laterza O, Savage MJ, Struyk A, Scheltens P, Teunissen CE, Burke J, Macaulay SL, Bråthen G, Sando SB, White LR, et al. A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging. Alzheimer's & Dementia (Amsterdam, Netherlands). 6: 201-209. PMID 28349119 DOI: 10.1016/J.Dadm.2017.02.004 |
0.444 |
|
| 2017 |
Vijverberg EG, Dols A, Krudop WA, Del Campo Milan M, Kerssens CJ, Gossink F, Prins ND, Stek ML, Scheltens P, Teunissen CE, Pijnenburg YA. Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. Alzheimer's & Dementia (Amsterdam, Netherlands). 7: 99-106. PMID 28337476 DOI: 10.1016/J.Dadm.2017.01.009 |
0.367 |
|
| 2017 |
Yu M, Engels MM, Hillebrand A, van Straaten EC, Gouw AA, Teunissen C, van der Flier WM, Scheltens P, Stam CJ. Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. Brain : a Journal of Neurology. PMID 28334883 DOI: 10.1093/Brain/Awx050 |
0.349 |
|
| 2017 |
Tijms BM, Bertens D, Slot RE, Gouw AA, Teunissen CE, Scheltens P, van der Flier WM, Visser PJ. Low normal CSF Aβ42 levels predict clinical progression in non-demented subjects. Annals of Neurology. PMID 28318059 DOI: 10.1002/Ana.24921 |
0.459 |
|
| 2017 |
Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR, Lovblad KO, Frisoni GB, Scheltens P. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging. 52: 167-182.e1. PMID 28317647 DOI: 10.1016/J.Neurobiolaging.2016.05.024 |
0.492 |
|
| 2017 |
de Wilde A, van Maurik IS, Kunneman M, Bouwman F, Zwan M, Willemse EA, Biessels GJ, Minkman M, Pel R, Schoonenboom NS, Smets EM, Wattjes MP, Barkhof F, Stephens A, van Lier EJ, ... ... Scheltens P, et al. Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimer's & Dementia (Amsterdam, Netherlands). 6: 143-151. PMID 28239639 DOI: 10.1016/J.Dadm.2017.01.003 |
0.498 |
|
| 2017 |
Handels RL, Vos SJ, Kramberger MG, Jelic V, Blennow K, van Buchem M, van der Flier W, Freund-Levi Y, Hampel H, Olde Rikkert M, Oleksik A, Pirtosek Z, Scheltens P, Soininen H, Teunissen C, et al. Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28216393 DOI: 10.1016/J.Jalz.2016.12.015 |
0.442 |
|
| 2017 |
Bertens D, Tijms BM, Scheltens P, Teunissen CE, Visser PJ. Unbiased estimates of cerebrospinal fluid β-amyloid 1-42 cutoffs in a large memory clinic population. Alzheimer's Research & Therapy. 9: 8. PMID 28193256 DOI: 10.1186/S13195-016-0233-7 |
0.367 |
|
| 2017 |
Hooghiemstra AM, Ramakers IH, Sistermans N, Pijnenburg YA, Aalten P, Hamel RE, Melis RJ, Verhey FR, Olde Rikkert MG, Scheltens P, van der Flier WM. Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. PMID 28177065 DOI: 10.1093/Gerona/Glx003 |
0.39 |
|
| 2017 |
Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FR, Aalten P, van Berckel BN, Scheltens P. Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia. Alzheimer's Research & Therapy. 9: 2. PMID 28093088 DOI: 10.1186/S13195-016-0228-4 |
0.359 |
|
| 2017 |
Claus JJ, Staekenborg SS, Holl DC, Roorda JJ, Schuur J, Koster P, Tielkes CE, Scheltens P. Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer's disease: Validation in a large memory clinic population. European Radiology. PMID 28083697 DOI: 10.1007/S00330-016-4726-3 |
0.422 |
|
| 2017 |
van Waalwijk van Doorn LJ, Gispert JD, Kuiperij HB, Claassen JA, Arighi A, Baldeiras I, Blennow K, Bozzali M, Castelo-Branco M, Cavedo E, Emek-Savaş DD, Eren E, Eusebi P, Farotti L, Fenoglio C, ... ... Scheltens P, et al. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease : Jad. PMID 28059783 DOI: 10.3233/Jad-160668 |
0.428 |
|
| 2017 |
Lemstra AW, Beer MHd, Teunissen CE, Schreuder C, Scheltens P, Flier WMvd, Sikkes SAM. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies Journal of Neurology, Neurosurgery, and Psychiatry. 88: 113-118. PMID 27794030 DOI: 10.1136/Jnnp-2016-313775 |
0.44 |
|
| 2017 |
Wilde Ad, Pelkmans W, Bouwman FH, Verwer J, Groot C, Buchem Mv, Zwan MD, Ossenkoppele R, Yaqub MM, Kunneman M, Smets EM, Barkhof F, Lammertsma AA, Stephens A, Lier Ev, ... ... Scheltens P, et al. The Impact Of Amyloid Pet On Diagnosis And Patient Management In An Unselected Memory Clinic Cohort: The Abide Project Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.08.004 |
0.419 |
|
| 2017 |
Vogel JW, Mattsson N, Medina YI, Strandberg O, Schöll M, Dansereau C, Villeneuve S, Flier WMvd, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R. Data-Driven Tau-Pet Covariance Networks Enhance Prediction Of Retrospective Cognitive Change In Alzheimer’S Disease Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.07.687 |
0.344 |
|
| 2017 |
Frisoni GB, Barkhof F, Farrar G, Raffa N, Gismondi R, Schmidt ME, Berkhof J, Boccardi M, Walker Z, Scheltens P, Schott JM, Molinuevo JL, Vellas B, Jessen F, Nordberg A, et al. THE AMYPAD-DX CONTROLLED TRIAL ON THE DIAGNOSTIC VALUE OF AMYLOID PET Alzheimer's & Dementia. 13: P1523. DOI: 10.1016/J.Jalz.2017.07.653 |
0.398 |
|
| 2017 |
Jansen IE, Teunissen CE, Barkhof F, Scheltens P, Posthuma D, van der Flier WM. ESTABLISHING THE EFFECT OF CODING VARIANTS ON ALZHEIMER’S DISEASE RELATED ENDOPHENOTYPES Alzheimer's & Dementia. 13: P1487-P1488. DOI: 10.1016/J.Jalz.2017.07.569 |
0.384 |
|
| 2017 |
Beker N, Ganz A, Rozemuller A, Scheltens P, Sikkes SA, Hoozemans JJ, Holstege H. COGNITIVE PERFORMANCE AND ALZHEIMER-ASSOCIATED PATHOLOGY IN THE CONTEXT OF EXTREME AGING Alzheimer's & Dementia. 13: P1472. DOI: 10.1016/J.Jalz.2017.07.546 |
0.416 |
|
| 2017 |
Lleó A, Alcolea D, Martinez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izagirre A, Reijs BLR, Farotti L, Fortea J, et al. Longitudinal Cerebrospinal Fluid Biomarker Trajectories Along The Alzheimer'S Disease Continuum: A Multicentre European Study Alzheimers & Dementia. 13: 924. DOI: 10.1016/J.Jalz.2017.07.359 |
0.369 |
|
| 2017 |
van der Flier WM, Scheltens NM, Heymans M, Rabinovici GD, Cohn-Sheehy B, Kramer JH, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Scheltens P, Tijms BM. PROMINENT NON-MEMORY DEFICITS IN AD ARE ASSOCIATED WITH A FASTER DISEASE PROGRESSION Alzheimer's & Dementia. 13: P912. DOI: 10.1016/J.Jalz.2017.07.335 |
0.359 |
|
| 2017 |
Vermunt L, Sikkes SAM, Hout Avd, Handels R, Bos I, Flier WMvd, Scheltens P, Terrera GM, Visser PJ. Duration Of Alzheimer’S Disease In The Preclinical, Prodromal And Dementia Stage: A Multi-State Model Analysis Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.07.212 |
0.318 |
|
| 2017 |
van Loenhoud AC, van der Flier WM, Wink AM, Groot C, Twisk JW, van Berckel BN, Barkhof F, Scheltens P, Ossenkoppele R. PREDICTING PROGRESSION IN PRE-DEMENTIA STAGES OF ALZHEIMER’S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE Alzheimer's & Dementia. 13: P581-P582. DOI: 10.1016/J.Jalz.2017.07.206 |
0.511 |
|
| 2017 |
Rhodius-Meester HFM, Liedes H, Wolfsgruber S, Coll-Padros N, Koikkalainen J, Kornhuber J, Peters O, Jessen F, Kleineidam L, Molinuevo JL, Rami L, Teunissen CE, Barkhof F, Sikkes SAM, Wesselman LMP, ... ... Scheltens P, et al. Prognosis Of Clinical Progression In Subjective Cognitive Decline Using A Clinical Decision Support System Alzheimers & Dementia. 13: 579. DOI: 10.1016/J.Jalz.2017.07.203 |
0.446 |
|
| 2017 |
Prins ND, Alam J, Chu H, Scheltens P. EVIDENCE THAT ORAL P38 MAPK ALPHA ANTAGONISM IMPROVES EPISODIC MEMORY IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE (AD) Alzheimer's & Dementia. 13: P576. DOI: 10.1016/J.Jalz.2017.07.197 |
0.353 |
|
| 2017 |
Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Bouwman FH, Prins ND, Teunissen CE, Dols A, Barkhof F, Berckel BNMv, Scheltens P, Sikkes SAM, Flier WMvd. Characterizing Individuals With Subjective Cognitive Decline: The Subjective Cognitive Impairment Cohort (Science) Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.07.143 |
0.456 |
|
| 2017 |
Boon BDC, Rozemuller A, Flier WMvd, Scheltens P, Teunissen CE, Bouwman FH. Mismatch Between Clinical And Neuropathological Diagnosis Of Dementia: How Can Biomarkers Help? Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.07.080 |
0.344 |
|
| 2017 |
Willemse EA, Vos AD, Herries EM, Andreasson U, Engelborghs S, Vanmechelen E, Flier WMvd, Scheltens P, Ladenson JH, Zetterberg H, Blennow K, Fagan AM, Bjerke M, Teunissen CE. Clinical Performance Of Neurogranin As A Cerebrospinal Fluid Biomarker For Alzheimer’S Disease: An Assay Comparison Study Alzheimers & Dementia. 13: 199. DOI: 10.1016/J.Jalz.2017.07.061 |
0.306 |
|
| 2017 |
Scheltens P. Biomarkers For The Diagnosis Of Alzheimer’S Disease Alzheimers & Dementia. 13: 180. DOI: 10.1016/J.Jalz.2017.07.031 |
0.312 |
|
| 2017 |
Maurik ISv, Slot RER, Verfaillie SCJ, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Wattjes MP, Berkhof J, Flier WMvd. Biomarker-Based Personalized Risk Estimates For Patients With Subjective Cognitive Decline Alzheimers & Dementia. 13: 177. DOI: 10.1016/J.Jalz.2017.07.022 |
0.449 |
|
| 2017 |
Westwood S, Hye A, Lleó A, Nevado-Holgado AJ, Baird AL, Wallin A, Leslie A, Jimenez B, Liu BY, Legido-Quigley C, Dima D, Ruvolo D, Holmes E, D'Hondt E, Westman E, ... ... Scheltens P, et al. DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION Alzheimer's & Dementia. 13: P174-P175. DOI: 10.1016/J.Jalz.2017.07.016 |
0.517 |
|
| 2017 |
Haan Jd, Kreeke Avd, Verbraak F, Nadyarnykh O, Teunissen CE, Barkhof F, Berckel BNMv, Scheltens P, Bouwman FH, Boer Jd. Amyloid Visualization In The Retina Of Alzheimer’S Disease Patients With Curcumin Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.897 |
0.434 |
|
| 2017 |
Bos I, Vos SJB, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni GB, Molinuevo JL, Wallin A, Lleó A, Popp J, Martinez-Lage P, Baird AL, Legido-Quigley C, Bertram L, Barkhof F, et al. European Medical Information Framework For Alzheimer’S Disease (Emif-Ad): The Biomarker Discovery Study Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.864 |
0.462 |
|
| 2017 |
Vos SJB, Verhey FRJ, Tsolaki M, Wahlund L, Waldemar G, Vandenberghe R, Frölich L, Lleó A, Scheltens P, Teunissen CE, Visser PJ. Using Emerging Cerebrospinal Fluid Markers To Characterize Suspected Non-Alzheimer’S Disease Pathophysiology (Snap) In Individuals With Mild Cognitive Impairment Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.845 |
0.365 |
|
| 2017 |
Wottschel V, Wink AM, Tijms BM, Collij L, Kuijer J, van der Flier WM, Scheltens P, Barkhof F. [P1-392]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA Alzheimer's & Dementia. 13: P417-P418. DOI: 10.1016/J.Jalz.2017.06.408 |
0.525 |
|
| 2017 |
Vos SJB, Gronenschild E, Jacobs HIL, Bos I, Scheltens P, Niemantsverdriet E, Engelborghs S, Verhey FRJ, Visser PJ. Characterization Of Suspected Non-Alzheimer’S Disease Pathophysiology (Snap) In Individuals With Mild Cognitive Impairment Using Neuroimaging Alzheimers & Dementia. 13: 414. DOI: 10.1016/J.Jalz.2017.06.403 |
0.374 |
|
| 2017 |
Westwood S, Baird AL, Hye A, Bos I, Vos SJ, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni GB, Molinuevo JL, Wallin A, Lleó A, Popp J, Martinez-Lage P, Snowden SG, et al. [P1-289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF Aβ OR AMYLOID-PET) IN THE EMIF-AD BIOMARKER DISCOVERY COHORT Alzheimer's & Dementia. 13: P361-P362. DOI: 10.1016/J.Jalz.2017.06.305 |
0.494 |
|
| 2017 |
Bouts MJRJ, Möller C, Hafkemeijer A, Swieten JCv, Dopper EGP, Flier WMvd, Vrenken H, Wink AM, Pijnenburg YAL, Scheltens P, Barkhof F, Grond Jvd, Rooij Md, Rombouts SARB. Mri-Based Classification Accuracy Of Dementia Type Is Determined By Mri Modality Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.2404 |
0.515 |
|
| 2017 |
Verfaillie SCJ, Slot RER, Dicks E, Prins ND, Overbeek JM, Scheltens P, Barkhof F, Flier WMvd, Tijms BM. Grey Matter Connectivity Is Related To A Steeper Loss Of Memory And Language Functioning Over Time In Patients With Subjective Cognitive Decline Alzheimers & Dementia. 13: 451. DOI: 10.1016/J.Jalz.2017.06.2384 |
0.456 |
|
| 2017 |
Kate Mt, Sudre CH, Braber Ad, Konijnenberg E, Cardoso MJ, Scheltens P, Ourselin S, Boomsma DI, Barkhof F, Visser PJ. White Matter Hyperintensities And Vascular Risk Factors In Cognitively Healthy Elderly Monozygotic Twin Pairs Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.2338 |
0.443 |
|
| 2017 |
Konijnenberg E, Braber Ad, Kate Mt, Adriaanse S, Yaqub MM, Uffelen KWv, Teunissen CE, Vanderstichele HM, Boomsma DI, Berckel BNMv, Scheltens P, Visser PJ. Twin Correlations For Amyloid Pathology Measured With Positron Emission Tomography And In Cerebrospinal Fluid In Cognitively Healthy Elderly Monozygotic Twin Pairs Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.2331 |
0.341 |
|
| 2017 |
Groot C, Weijden CWJvd, Flier WMvd, Loenhoud ACv, Berckel BNMv, Barkhof F, Koene T, Teunissen CE, Scheltens P, Ossenkoppele R. EFFECT OF APOE-ε2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER’S DISEASE Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.2328 |
0.462 |
|
| 2017 |
Braber Ad, Prent N, Kate Mt, Konijnenberg E, Barkhof F, Berckel BNMv, Scheltens P, Boomsma DI, Visser PJ. Early Alterations In Resting-State Functional Connectivity Is Associated With Amyloid Pathology In Cognitively Healthy Elderly Monozygotic Twins Alzheimers & Dementia. 13: 429. DOI: 10.1016/J.Jalz.2017.06.2326 |
0.495 |
|
| 2017 |
Sikkes SAM, Gehrels A, Tijms BM, Habert M, Hampel H, Epelbaum S, Tandetnik C, Bakardjian H, Scheltens P, Dubois B. Does Brain Amyloid Deposition Impact Everyday Functioning In Subjects With Cognitive Complaints? Results From The Insight Cohort Alzheimers & Dementia. 13: 1406. DOI: 10.1016/J.Jalz.2017.06.2172 |
0.344 |
|
| 2017 |
Timmers T, Wolters EE, Ossenkoppele R, Verfaillie SCJ, Weijden CWJvd, Golla SSV, Slot RER, Wesselman LMP, Overbeek JM, Schmidt ME, Yaqub MM, Lammertsma AA, Scheltens P, Flier WMvd, Berckel BNMv. [ 18 F]Av1451 Binding Potential In Relation To Amyloid Status And Cognition In Subjects With Subjective Cognitive Decline Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.2087 |
0.336 |
|
| 2017 |
Jutten RJ, Harrison J, Kjoe PLM, Jong FJd, Aleman A, Ritchie CW, Scheltens P, Sikkes SAM. Quality Aspects Of A Novel Cognitive-Functional Composite For The Measurement Of Disease Progression In Alzheimer’S Disease: Feasibility, Test-Retest Reliability And Practice Effects Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.1872 |
0.332 |
|
| 2017 |
Leijenaar JF, Pelkmans W, Rozemuller A, Bouwman FH, Flier WMvd, Scheltens P, Barkhof F, Prins ND. Clinical And Radiological Findings In Patients With Pathologically Confirmed Caa Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.1639 |
0.425 |
|
| 2017 |
Verfaillie SC, Binette AP, Vachon-Presseau É, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JC, Villeneuve S. [P3-407]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER's DISEASE Alzheimer's & Dementia. 13: P1120-P1121. DOI: 10.1016/J.Jalz.2017.06.1624 |
0.394 |
|
| 2017 |
Lotjonen J, Koikkalainen J, Meester HFR, Flier WMvd, Scheltens P, Barkhof F, Erkinjuntti T. Computed Rating Scales For Cognitive Disorders From Mri Alzheimers & Dementia. 13: 1108. DOI: 10.1016/J.Jalz.2017.06.1602 |
0.419 |
|
| 2017 |
Dicks E, Tijms BM, Gouw AA, Benedictus MR, Barkhof F, Scheltens P, Flier WMvd. Grey Matter Connectivity Is Associated With The Rate Of Cognitive Decline In Mild Cognitive Impairment Alzheimers & Dementia. 13: 69. DOI: 10.1016/J.Jalz.2017.06.1591 |
0.467 |
|
| 2017 |
de Leeuw FA, Peeters CF, Kester MI, Harms AC, Hankemeier T, Struys EA, Demirkan A, Scheltens P, van Vlijmen HW, van de Wiel MA, van Duijn CM, van der Flier WM, Teunissen CE. [P3-226]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER's DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES Alzheimer's & Dementia. 13: P1024-P1025. DOI: 10.1016/J.Jalz.2017.06.1439 |
0.376 |
|
| 2017 |
Skillback T, Mattsson N, Hansson K, Mirgorodskaya E, Flier WMvd, Scheltens P, Duits F, Hansson O, Teunissen CE, Blennow K, Zetterberg H, Gobom J. Pleiotrophin, A New Biomarker For Ad, Identified Using A Novel Strategy In Clinical Proteomics Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.1285 |
0.319 |
|
| 2017 |
Verfaillie SCJ, Witteman J, Slot RER, Pruis IJ, Vermaat LEW, Mulder J, Schiller NO, Scheltens P, Berckel BNMv, Flier WMvd, Sikkes SAM. The Effects Of Amyloid On Semantic Complexity In Spontaneous Speech In Subjective Cognitive Decline Alzheimers & Dementia. 13. DOI: 10.1016/J.Jalz.2017.06.1130 |
0.325 |
|
| 2017 |
Kate Mt, Tijms BM, Konijnenberg E, Braber Ad, Boomsma DI, Scheltens P, Barkhof F, Visser PJ. Correlation Of Grey Matter Network Measures In Cognitively Healthy Elderly Monozygotic Twin Pairs Alzheimers & Dementia. 13: 783. DOI: 10.1016/J.Jalz.2017.06.1054 |
0.443 |
|
| 2017 |
van der Zande JJ, Gouw AA, Scheltens P, Stam CJ, Lemstra AW. [P1-244]: DISCRIMINATION BETWEEN DEMENTIA WITH LEWY BODIES (DLB), ALZHEIMER's DISEASE (AD) AND MIXED PATHOLOGY USING ELECTRO-ENCEPHALOGRAPHY (EEG) Alzheimer's & Dementia. 13: P338-P339. DOI: 10.1016/J.Jalz.2017.06.064 |
0.459 |
|
| 2017 |
Scheltens P. De toekomst van Alzheimer Zorgvisie Ict. 46: 47-47. DOI: 10.1007/S41187-016-0237-8 |
0.341 |
|
| 2016 |
Scheltens NME, Kuyper IS, Boellaard R, Barkhof F, Teunissen CE, Broersen LM, Lansbergen MM, van der Flier WM, van Berckel BNM, Scheltens P. Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 2: 233-240. PMID 29067310 DOI: 10.1016/J.Trci.2016.07.004 |
0.451 |
|
| 2016 |
Verfaillie SC, Tijms B, Versteeg A, Benedictus MR, Bouwman FH, Scheltens P, Barkhof F, Vrenken H, van der Flier WM. Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. Alzheimer's & Dementia (Amsterdam, Netherlands). 5: 43-52. PMID 28054027 DOI: 10.1016/J.Dadm.2016.10.007 |
0.559 |
|
| 2016 |
Slot RE, Van Harten AC, Kester MI, Jongbloed W, Bouwman FH, Teunissen CE, Scheltens P, Veerhuis R, van der Flier WM. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. Journal of Alzheimer's Disease : Jad. PMID 28035918 DOI: 10.3233/Jad-151068 |
0.396 |
|
| 2016 |
Leijenaar JF, Scheltens P. From corticocentrism to leucocentrism or both. Brain : a Journal of Neurology. PMID 28007999 DOI: 10.1093/Brain/Aww311 |
0.367 |
|
| 2016 |
Jokinen H, Melkas S, Madureira S, Verdelho A, Ferro JM, Fazekas F, Schmidt R, Scheltens P, Barkhof F, Wardlaw JM, Inzitari D, Pantoni L, Erkinjuntti T. Cognitive reserve moderates long-term cognitive and functional outcome in cerebral small vessel disease. Journal of Neurology, Neurosurgery, and Psychiatry. 87: 1296-1302. PMID 27951523 DOI: 10.1136/Jnnp-2016-313914 |
0.481 |
|
| 2016 |
Louwersheimer E, Cohn-Hokke PE, Pijnenburg YA, Weiss MM, Sistermans EA, Rozemuller AJ, Hulsman M, van Swieten JC, van Duijn CM, Barkhof F, Koene T, Scheltens P, Van der Flier WM, Holstege H. Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE-ɛ4 Homozygosity. Journal of Alzheimer's Disease : Jad. PMID 27911290 DOI: 10.3233/Jad-160091 |
0.473 |
|
| 2016 |
Liao W, Hamel RE, Olde Rikkert MG, Oosterveld SM, Aalten P, Verhey FR, Scheltens P, Sistermans N, Pijnenburg YA, van der Flier WM, Ramakers IH, Melis RJ. A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands. Bmc Neurology. 16: 242. PMID 27884130 DOI: 10.1186/S12883-016-0750-9 |
0.419 |
|
| 2016 |
van Straaten EC, de Waal H, Lansbergen MM, Scheltens P, Maestu F, Nowak R, Hillebrand A, Stam CJ. Magnetoencephalography for the Detection of Intervention Effects of a Specific Nutrient Combination in Patients with Mild Alzheimer's Disease: Results from an Exploratory Double-Blind, Randomized, Controlled Study. Frontiers in Neurology. 7: 161. PMID 27799918 DOI: 10.3389/Fneur.2016.00161 |
0.367 |
|
| 2016 |
Dauwan M, van der Zande JJ, van Dellen E, Sommer IE, Scheltens P, Lemstra AW, Stam CJ. Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 4: 99-106. PMID 27722196 DOI: 10.1016/J.Dadm.2016.07.003 |
0.43 |
|
| 2016 |
Jansen WJ, Handels RL, Visser PJ, Aalten P, Bouwman F, Claassen J, van Domburg P, Hoff E, Hoogmoed J, Leentjens AF, Rikkert MO, Oleksik AM, Smid M, Scheltens P, Wolfs C, et al. The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients. Journal of Alzheimer's Disease : Jad. PMID 27716658 DOI: 10.3233/Jad-160126 |
0.324 |
|
| 2016 |
Leeuwis AE, Benedictus MR, Kuijer JP, Binnewijzend MA, Hooghiemstra AM, Verfaillie SC, Koene T, Scheltens P, Barkhof F, Prins ND, van der Flier WM. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 27693109 DOI: 10.1016/J.Jalz.2016.08.013 |
0.534 |
|
| 2016 |
Hafkemeijer A, Möller C, Dopper EG, Jiskoot LC, van den Berg-Huysmans AA, van Swieten JC, van der Flier WM, Vrenken H, Pijnenburg YA, Barkhof F, Scheltens P, van der Grond J, Rombouts SA. A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 27662284 DOI: 10.3233/Jad-150695 |
0.547 |
|
| 2016 |
Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer's disease: the path to 2025. Alzheimer's Research & Therapy. 8: 39. PMID 27646601 DOI: 10.1186/S13195-016-0207-9 |
0.396 |
|
| 2016 |
Fuermaier AB, Piersma D, de Waard D, Davidse RJ, de Groot J, Doumen MJ, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, Brouwer WH, Tucha O. Assessing fitness to drive - A validation study on patients with Mild Cognitive Impairment. Traffic Injury Prevention. 0. PMID 27623685 DOI: 10.1080/15389588.2016.1232809 |
0.395 |
|
| 2016 |
Boelaarts L, Scheltens P, de Jonghe J. Does MRI Increase the Diagnostic Confidence of Physicians in an Outpatient Memory Clinic. Dementia and Geriatric Cognitive Disorders Extra. 6: 242-51. PMID 27489558 DOI: 10.1159/000445711 |
0.359 |
|
| 2016 |
Collij LE, Heeman F, Kuijer JP, Ossenkoppele R, Benedictus MR, Möller C, Verfaillie SC, Sanz-Arigita EJ, van Berckel BN, van der Flier WM, Scheltens P, Barkhof F, Wink AM. Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. Radiology. 152703. PMID 27383395 DOI: 10.1148/Radiol.2016152703 |
0.518 |
|
| 2016 |
Madureira S, Verdelho A, Moleiro C, Santos C, Scheltens P, Gouw A, Ferro J. White Matter Changes and Cognitive Decline in a Ten-Year Follow-Up Period: A Pilot Study on a Single-Center Cohort from the Leukoaraiosis and Disability Study. Dementia and Geriatric Cognitive Disorders. 41: 303-313. PMID 27380560 DOI: 10.1159/000447121 |
0.357 |
|
| 2016 |
Vijverberg EG, Wattjes MP, Dols A, Krudop WA, Möller C, Peters A, Kerssens CJ, Gossink F, Prins ND, Stek ML, Scheltens P, van Berckel BN, Barkhof F, Pijnenburg YA. Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes. Journal of Alzheimer's Disease : Jad. PMID 27372646 DOI: 10.3233/Jad-160285 |
0.435 |
|
| 2016 |
Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. PMID 27371494 DOI: 10.1212/Wnl.0000000000002923 |
0.433 |
|
| 2016 |
Chételat G, Ossenkoppele R, Villemagne VL, Perrotin A, Landeau B, Mézenge F, Jagust WJ, Dore V, Miller BL, Egret S, Seeley WW, van der Flier WM, La Joie R, Ames D, van Berckel BN, ... Scheltens P, et al. Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. Brain : a Journal of Neurology. PMID 27357349 DOI: 10.1093/Brain/Aww159 |
0.544 |
|
| 2016 |
Benedictus MR, Leeuwis AE, Binnewijzend MA, Kuijer JP, Scheltens P, Barkhof F, van der Flier WM, Prins ND. Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. European Radiology. PMID 27334014 DOI: 10.1007/S00330-016-4450-Z |
0.534 |
|
| 2016 |
Sassi C, Nalls MA, Ridge PG, Gibbs JR, Ding J, Lupton MK, Troakes C, Lunnon K, Al-Sarraj S, Brown KS, Medway C, Clement N, Lord J, Turton J, Bras J, ... ... Scheltens P, et al. ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging. PMID 27289440 DOI: 10.1016/J.Neurobiolaging.2016.04.004 |
0.384 |
|
| 2016 |
Cohn-Hokke PE, Holstege H, Weiss MM, van der Flier WM, Barkhof F, Sistermans EA, Pijnenburg YA, van Swieten JC, Meijers-Heijboer H, Scheltens P. A novel CCM2 variant in a family with non-progressive cognitive complaints and cerebral microbleeds. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. PMID 27277535 DOI: 10.1002/Ajmg.B.32468 |
0.512 |
|
| 2016 |
Engels MM, Hillebrand A, van der Flier WM, Stam CJ, Scheltens P, van Straaten EC. Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer's Disease. An MEG Study with Virtual Electrodes. Frontiers in Human Neuroscience. 10: 238. PMID 27242496 DOI: 10.3389/Fnhum.2016.00238 |
0.407 |
|
| 2016 |
Kerssens CJ, Krudop WA, Prins ND, van Berckel BN, Rozemuller A, Seeley WW, Scheltens P, Stek ML, Pijnenburg YA. Schizophrenia as a mimic of behavioral variant frontotemporal dementia. Neurocase. 1-4. PMID 27223596 DOI: 10.1080/13554794.2016.1187178 |
0.356 |
|
| 2016 |
Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, et al. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimer's Research & Therapy. 8: 18. PMID 27176461 DOI: 10.1186/S13195-016-0189-7 |
0.426 |
|
| 2016 |
Vijverberg EG, Dols A, Krudop WA, Peters A, Kerssens CJ, van Berckel BN, Wattjes MP, Barkhof F, Gossink F, Prins ND, Stek ML, Scheltens P, Pijnenburg YA. Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome. Dementia and Geriatric Cognitive Disorders. 41: 210-9. PMID 27160162 DOI: 10.1159/000444849 |
0.466 |
|
| 2016 |
Konijnenberg E, Fereshtehnejad SM, Kate MT, Eriksdotter M, Scheltens P, Johannsen P, Waldemar G, Visser PJ. Early-Onset Dementia: Frequency, Diagnostic Procedures, and Quality Indicators in Three European Tertiary Referral Centers. Alzheimer Disease and Associated Disorders. PMID 27158877 DOI: 10.1097/Wad.0000000000000152 |
0.333 |
|
| 2016 |
Staekenborg SS, Pijnenburg YA, Lemstra AW, Scheltens P, Vd Flier WM. Dementia and Rapid Mortality: Who is at Risk? Journal of Alzheimer's Disease : Jad. PMID 27104894 DOI: 10.3233/Jad-151063 |
0.346 |
|
| 2016 |
Dauwan M, van Dellen E, van Boxtel L, van Straaten EC, de Waal H, Lemstra AW, Gouw AA, van der Flier WM, Scheltens P, Sommer IE, Stam CJ. EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls. Neurobiology of Aging. 41: 122-9. PMID 27103525 DOI: 10.1016/J.Jalz.2016.06.075 |
0.375 |
|
| 2016 |
Janssen N, Handels RL, Koehler S, Ramakers IH, Hamel RE, Olde Rikkert MG, Scheltens P, Bouwman FH, van der Flier WM, Wolfs CA, de Vugt ME, Evers SM, Verhey FR. Combinations of Service Use Types of People With Early Cognitive Disorders. Journal of the American Medical Directors Association. PMID 27073042 DOI: 10.1016/J.Jamda.2016.02.034 |
0.303 |
|
| 2016 |
Handels RL, Joore MA, Vos SJ, Aalten P, Ramakers IH, Rikkert MO, Scheltens P, Jansen WJ, Visser PJ, van Berckel BM, van Domburg P, Smid M, Hoff E, Hoogmoed J, Bouwman F, et al. Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort. Journal of Alzheimer's Disease : Jad. PMID 27031483 DOI: 10.3233/Jad-151120 |
0.419 |
|
| 2016 |
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 12: 292-323. PMID 27012484 DOI: 10.1016/J.Jalz.2016.02.002 |
0.387 |
|
| 2016 |
Schott JM, Crutch SJ, Carrasquillo MM, Uphill J, Shakespeare TJ, Ryan NS, Yong KX, Lehmann M, Ertekin-Taner N, Graff-Radford NR, Boeve BF, Murray ME, Khan QU, Petersen RC, Dickson DW, ... ... Scheltens P, et al. Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 26993346 DOI: 10.1016/J.Jalz.2016.01.010 |
0.394 |
|
| 2016 |
Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, ... ... Scheltens P, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. The Lancet. Neurology. 15: 455-532. PMID 26987701 DOI: 10.1016/S1474-4422(16)00062-4 |
0.428 |
|
| 2016 |
Lacour A, Espinosa A, Louwersheimer E, Heilmann S, Hernández I, Wolfsgruber S, Fernández V, Wagner H, Rosende-Roca M, Mauleón A, Moreno-Grau S, Vargas L, Pijnenburg YA, Koene T, Rodríguez-Gómez O, ... ... Scheltens P, et al. Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. Molecular Psychiatry. PMID 26976043 DOI: 10.1038/Mp.2016.18 |
0.47 |
|
| 2016 |
Gossink FT, Dols A, Krudop WA, Sikkes SA, Kerssens CJ, Prins ND, Scheltens P, Stek ML, Pijnenburg YA. Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia. Journal of Alzheimer's Disease : Jad. PMID 26967225 DOI: 10.3233/Jad-151198 |
0.317 |
|
| 2016 |
Harper L, Fumagalli GG, Barkhof F, Scheltens P, O'Brien JT, Bouwman F, Burton EJ, Rohrer JD, Fox NC, Ridgway GR, Schott JM. MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain : a Journal of Neurology. PMID 26936938 DOI: 10.1093/Brain/Aww005 |
0.488 |
|
| 2016 |
Louwersheimer E, Wolfsgruber S, Espinosa A, Lacour A, Heilmann-Heimbach S, Alegret M, Hernández I, Rosende-Roca M, Tárraga L, Boada M, Kornhuber J, Peters O, Frölich L, Hüll M, Rüther E, ... ... Scheltens P, et al. Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 26921674 DOI: 10.1016/J.Jalz.2016.01.006 |
0.498 |
|
| 2016 |
Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer's disease. Lancet (London, England). PMID 26921134 DOI: 10.1016/S0140-6736(15)01124-1 |
0.391 |
|
| 2016 |
Louwersheimer E, Keulen MA, Steenwijk MD, Wattjes MP, Jiskoot LC, Vrenken H, Teunissen CE, van Berckel BN, van der Flier WM, Scheltens P, van Swieten JC, Pijnenburg YA. Heterogeneous Language Profiles in Patients with Primary Progressive Aphasiadue to Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 26890751 DOI: 10.3233/Jad-150812 |
0.43 |
|
| 2016 |
Möller C, Hafkemeijer A, Pijnenburg YA, Rombouts SA, van der Grond J, Dopper E, van Swieten J, Versteeg A, Steenwijk MD, Barkhof F, Scheltens P, Vrenken H, van der Flier WM. Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging. 38: 21-31. PMID 26827640 DOI: 10.1016/J.Neurobiolaging.2015.10.020 |
0.549 |
|
| 2016 |
Claus JJ, Staekenborg SS, Roorda JJ, Stevens M, Herderschee D, Maarschalkerweerd WV, Schuurmans L, Tielkes CE, Koster P, Bavinck C, Scheltens P. Low Prevalence of Mixed Dementia in a Cohort of 2, 000 Elderly Patients in a Memory Clinic Setting. Journal of Alzheimer's Disease : Jad. PMID 26757192 DOI: 10.3233/Jad-150796 |
0.457 |
|
| 2016 |
van Waalwijk van Doorn LJ, Koel-Simmelink MJ, Haußmann U, Klafki H, Struyfs H, Linning P, Knölker HJ, Twaalfhoven H, Kuiperij HB, Engelborghs S, Scheltens P, Verbeek MM, Vanmechelen E, Wiltfang J, Teunissen CE. Validation of soluble APP assays as diagnostic CSF biomarkers for neurodegenerative diseases. Journal of Neurochemistry. PMID 26748905 DOI: 10.1111/Jnc.13527 |
0.305 |
|
| 2016 |
Rosenberger AF, Morrema TH, Gerritsen WH, van Haastert ES, Snkhchyan H, Hilhorst R, Rozemuller AJ, Scheltens P, van der Vies SM, Hoozemans JJ. Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology. Journal of Neuroinflammation. 13: 4. PMID 26732432 DOI: 10.1186/S12974-015-0470-X |
0.419 |
|
| 2016 |
Nikolcheva T, Lasser R, Ostrowitzki S, Scheltens P, Boada M, Dubois B, Dorflinger E, Volz D, Eichenlaub U, Rabe C, Bittner T, Schmitz M, Edgar C, Garibaldi G, Fontoura P, et al. CSF and amyloid pet biomarker data from scarlet road - a global Phase 3 study of gantenerumab in patients with prodromal AD Neurobiology of Aging. 39. DOI: 10.1016/J.Neurobiolaging.2016.01.124 |
0.347 |
|
| 2016 |
Prins ND, Bergeron D, Groot C, Loenhoud ACv, Laforce R, Berckel BNMv, Barkhof F, Flier WMvd, Scheltens P, Ossenkoppele R. Impact Of Co-Morbid Amyloid Pathology On Clinical Phenotype Of Patients With Vascular Cognitive Disorders Alzheimers & Dementia. 12: 472. DOI: 10.1016/J.Jalz.2016.06.926 |
0.485 |
|
| 2016 |
Maurik ISv, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Wattjes M, Berkhof J, Flier WMvd. Personalized Risk Estimates For Mci Patients: Taking Biomarkers Into The Clinic Alzheimers & Dementia. 12: 393. DOI: 10.1016/J.Jalz.2016.06.742 |
0.404 |
|
| 2016 |
Sikkes SA, Hooghiemstra AM, Pijnenburg YA, Scheltens P. F5-05-01: THE PAST, PRESENT, AND FUTURE OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING ASSESSMENTS IN ALZHEIMER'S DISEASE Alzheimer's & Dementia. 12: P372-P373. DOI: 10.1016/J.Jalz.2016.06.699 |
0.361 |
|
| 2016 |
Tijms BM, Kate Mt, Gouw AA, Teunissen CE, Barkhof F, Scheltens P, Flier WMvd. Grey Matter Connectivity Is Associated With Time To Clinical Progression In Mild Cognitive Impairment, Independent Of Amyloid Status Alzheimers & Dementia. 12: 303. DOI: 10.1016/J.Jalz.2016.06.549 |
0.511 |
|
| 2016 |
Scheltens P, Blennow K, Rowe CC, Fox NC, Lovestone S, DeCarli C, Snyder HM, Amouyel P, Carrillo MC. FTS3-01-03: Biomarkers for Vascular Contributions to Dementia Alzheimer's & Dementia. 12: P276-P277. DOI: 10.1016/J.Jalz.2016.06.2386 |
0.327 |
|
| 2016 |
Hooghiemstra AM, Visser PJ, Slot RER, Teunissen CE, Scheltens P, Flier WMvd. Alzheimer’S Disease Patients With Osas History Have Higher Csf Tau Levels Alzheimers & Dementia. 12: 1115. DOI: 10.1016/J.Jalz.2016.06.2316 |
0.34 |
|
| 2016 |
van Loenhoud AC, Wink AM, Groot C, Verfaillie SC, Barkhof F, van Berckel BN, Scheltens P, van der Flier WM, Ossenkoppele R. P4-191: A Novel Neuroimaging Approach to Capture Cognitive Reserve Alzheimer's & Dementia. 12: P1095-P1096. DOI: 10.1016/J.Jalz.2016.06.2283 |
0.433 |
|
| 2016 |
Slot RER, Sikkes SAM, Verfaillie SCJ, Wolfsgruber S, Brodaty H, Buckley RF, Hampel H, Kochan NA, Luck T, Maruff P, Molinuevo JL, Kornhuber J, Reisberg B, Riedel-Heller SG, Roehr S, ... ... Scheltens P, et al. Subjective Cognitive Decline And Progression To Dementia Due To Ad And Non-Ad In Memory Clinic And Community-Based Cohorts Alzheimers & Dementia. 12: 1073. DOI: 10.1016/J.Jalz.2016.06.2245 |
0.42 |
|
| 2016 |
Vermunt L, Konijnenberg E, Kate Mt, Braber Ad, Yaqub MM, Serné E, Boomsma DI, Scheltens P, Berckel BNMv, Visser PJ. Large-Vessel Disease And [18F]Flutemetamol-Amyloid Deposition In Cognitively Healthy Elderly Twins Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.2237 |
0.352 |
|
| 2016 |
Tijms BM, Bertens D, Zwan MD, Slot RER, Teunissen CE, Flier WMvd, Scheltens P, Visser PJ. Amyloid Levels In The Normal Range Are Predictive For Incident Dementia In Non-Demented Elderly Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.2203 |
0.343 |
|
| 2016 |
Verfaillie SCJ, Slot RER, Tijms BM, Bouwman FH, Benedictus M, Overbeek J, Koene T, Vrenken H, Scheltens P, Barkhof F, Flier WMvd. Thinner Cortical Thickness In Patients With Subjective Cognitive Decline Is Related To Poor Memory Performance And Faster Decline Of Executive Function Alzheimers & Dementia. 12: 774. DOI: 10.1016/J.Jalz.2016.06.184 |
0.465 |
|
| 2016 |
Scheltens NM, Tijms BM, Koene T, Barkhof F, Teunissen CE, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Cohn-Sheehy B, Rabinovici GD, Miller B, Kramer J, Scheltens P, van der Flier WM. P3-144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts Alzheimer's & Dementia. 12: P873-P874. DOI: 10.1016/J.Jalz.2016.06.1804 |
0.548 |
|
| 2016 |
Kate Mt, Visser PJ, Flier WMvd, Scheltens P, Barkhof F, Tijms BM. Atrophy Patterns Predicting Cognitive Decline In Non-Demented Subjects Are Independent Of Amyloid Pathology Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.177 |
0.494 |
|
| 2016 |
Sikkes SAM, Jutten RJ, Harrison J, Jong FJd, Aleman A, Ritchie CW, Scheltens P. Capturing Changes In Cognition: The Needs And Wishes Of Dementia Researchers And Clinicians Alzheimers & Dementia. 12: 748. DOI: 10.1016/J.Jalz.2016.06.1560 |
0.348 |
|
| 2016 |
Zande JJvd, Dauwan M, Dellen EV, Scheltens P, Lemstra AW, Stam CJ. Applying Random Forest Machine Learning To Diagnose Alzheimer’S Disease And Dementia With Lewy Bodies: A Combination Of Electroencephalography (Eeg), Clinical Parameters And Biomarkers Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.1501 |
0.302 |
|
| 2016 |
Leijenaar JF, Maurik ISv, Kuijer J, Flier WMvd, Scheltens P, Barkhof F, Prins ND. Cerebral Blood Flow Measured With Phase-Contrast Mri In Ad, Mci And Controls Alzheimers & Dementia. 12: 706. DOI: 10.1016/J.Jalz.2016.06.1389 |
0.444 |
|
| 2016 |
Groot C, van Loenhoud AC, van Berckel BN, Barkhof F, Koene T, Teunissen CE, Scheltens P, van der Flier WM, Ossenkoppele R. IC-P-103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer’s Disease Alzheimer's & Dementia. 12: P78-P79. DOI: 10.1016/J.Jalz.2016.06.133 |
0.449 |
|
| 2016 |
Boon BDC, Hoozemans JM, Klaver R, Berg WDVd, Kamphorst W, Voorn P, Scheltens P, Bouwman FH, Rozemuller A. Different Pathological Distribution Pattern Of Phosphorylated Tau And Microglia In Amnestic And Non-Amnestic Alzheimer’S Disease Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.1090 |
0.304 |
|
| 2016 |
van der Zande JJ, Wattjes M, Scheltens P, Lemstra AW. P1-298: The Influence of Concomitant Alzheimer Pathology on Atrophy in Dementia with Lewy Bodies (DLB): A Comparative MRI Study Alzheimer's & Dementia. 12: P535-P535. DOI: 10.1016/J.Jalz.2016.06.1048 |
0.428 |
|
| 2016 |
Tijms BM, Kate Mt, Verfaillie SCJ, Gouw AA, Teunissen CE, Barkhof F, Scheltens P, Flier WMvd. Grey Matter Connectivity Is Associated With Clinical Progression In Non-Demented, Amyloid Positive Patients Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.072 |
0.459 |
|
| 2016 |
Braber Ad, Konijnenberg E, Kate Mt, Tijms BM, Barkhof F, Boomsma DI, Scheltens P, Visser PJ. Correlation of cortical thickness in cognitively healthy elderly monozygotic twin pairs Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.069 |
0.452 |
|
| 2016 |
Konijnenberg E, Braber Ad, Kate Mt, Adriaanse S, Yaqub MM, Boomsma DI, Scheltens P, Berckel BNMv, Visser PJ. Concordance Of [18F]Flutemetamol Amyloid Deposition In Cognitively Healthy Elderly Monozygotic Twin Pairs Alzheimers & Dementia. 12: 23. DOI: 10.1016/J.Jalz.2016.06.027 |
0.322 |
|
| 2016 |
Wilde Ad, Flier WMvd, Bouwman FH, Ossenkoppele R, Pelkmans W, Groot C, Zwan MD, Yaqub MM, Newman V, Lammertsma AA, Berckel BNMv, Scheltens P. The Diagnostic Value Of Amyloid Pet In An Unselected Cohort Of Memory Clinic Patients Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.06.021 |
0.311 |
|
| 2015 |
Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimer's & Dementia (Amsterdam, Netherlands). 1: 505-12. PMID 27239528 DOI: 10.1016/J.Dadm.2015.11.001 |
0.329 |
|
| 2015 |
Del Campo Milan M, Zuroff L, Jimenez CR, Scheltens P, Teunissen CE. Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease? Alzheimer's & Dementia (Amsterdam, Netherlands). 1: 75-80. PMID 27239494 DOI: 10.1016/J.Dadm.2014.11.008 |
0.44 |
|
| Show low-probability matches. |
